-
1
-
-
0035499267
-
Stem cells, cancer, and cancer stem cells
-
1:CAS:528:DC%2BD3MXot1ahs7c%3D 11689955
-
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
-
(2001)
Nature
, vol.414
, pp. 105-111
-
-
Reya, T.1
Morrison, S.J.2
Clarke, M.F.3
Weissman, I.L.4
-
2
-
-
36148991764
-
Cancer stem cells in solid tumors
-
1:CAS:528:DC%2BD2sXhtlGhu73N 18023337
-
Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18:460-6.
-
(2007)
Curr Opin Biotechnol
, vol.18
, pp. 460-466
-
-
Ailles, L.E.1
Weissman, I.L.2
-
3
-
-
34047096557
-
Cancer stem cells: Models and concepts
-
1:CAS:528:DC%2BD2sXisV2jtr8%3D 17002552
-
Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-84.
-
(2007)
Annu Rev Med
, vol.58
, pp. 267-284
-
-
Dalerba, P.1
Cho, R.W.2
Clarke, M.F.3
-
4
-
-
33846029123
-
A perivascular niche for brain tumor stem cells
-
1:CAS:528:DC%2BD2sXhtFClsLY%3D 17222791
-
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82.
-
(2007)
Cancer Cell
, vol.11
, pp. 69-82
-
-
Calabrese, C.1
Poppleton, H.2
Kocak, M.3
Hogg, T.L.4
Fuller, C.5
Hamner, B.6
-
5
-
-
58149380742
-
Stem cell concepts renew cancer research
-
1:CAS:528:DC%2BD1cXhsFWmtr3M 19064739
-
Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793-807.
-
(2008)
Blood
, vol.112
, pp. 4793-4807
-
-
Dick, J.E.1
-
6
-
-
43749084585
-
Recent advances in cancer stem cells
-
1:CAS:528:DC%2BD1cXmsVartbs%3D 18356041
-
Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev. 2008;18:48-53.
-
(2008)
Curr Opin Genet Dev
, vol.18
, pp. 48-53
-
-
Cho, R.W.1
Clarke, M.F.2
-
7
-
-
70349547152
-
Identification and targeting of cancer stem cells
-
2887758 1:CAS:528:DC%2BD1MXhtlynsL7I 19708024
-
Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays. 2009;31:1038-49.
-
(2009)
Bioessays
, vol.31
, pp. 1038-1049
-
-
Schatton, T.1
Frank, N.Y.2
Frank, M.H.3
-
8
-
-
77957797200
-
Neoplastic stem cells: Current concepts and clinical perspectives
-
20185329
-
Schulenburg A, Bramswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, et al. Neoplastic stem cells: current concepts and clinical perspectives. Crit Rev Oncol Hematol. 2010;76:79-98.
-
(2010)
Crit Rev Oncol Hematol
, vol.76
, pp. 79-98
-
-
Schulenburg, A.1
Bramswig, K.2
Herrmann, H.3
Karlic, H.4
Mirkina, I.5
Hubmann, R.6
-
9
-
-
77953811725
-
Cancer stem cells: Back to Darwin?
-
20359535
-
Greaves M. Cancer stem cells: back to Darwin? Semin Cancer Biol. 2010;20(2):65-70.
-
(2010)
Semin Cancer Biol
, vol.20
, Issue.2
, pp. 65-70
-
-
Greaves, M.1
-
10
-
-
33750313208
-
Cancer stem cells - Perspectives on current status and future directions: AACR Workshop on cancer stem cells
-
1:CAS:528:DC%2BD28XhtVamsr3I 16990346
-
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339-44.
-
(2006)
Cancer Res
, vol.66
, pp. 9339-9344
-
-
Clarke, M.F.1
Dick, J.E.2
Dirks, P.B.3
Eaves, C.J.4
Jamieson, C.H.5
Jones, D.L.6
-
11
-
-
47049127238
-
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: Implications for the biology, management, and therapy of the disease
-
1:CAS:528:DC%2BD1cXhtVWqu7zI 18540942
-
Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol. 2008;142(3):361-78.
-
(2008)
Br J Haematol
, vol.142
, Issue.3
, pp. 361-378
-
-
Valent, P.1
-
12
-
-
33646448921
-
Biology of normal and acute myeloid leukemia stem cells
-
1:CAS:528:DC%2BD28XosVKrug%3D%3D 16533740
-
Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2005;82:389-96.
-
(2005)
Int J Hematol
, vol.82
, pp. 389-396
-
-
Dick, J.E.1
Lapidot, T.2
-
13
-
-
3242754448
-
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity
-
1:CAS:528:DC%2BD2cXlt1Wmuro%3D 15170211
-
Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738-43.
-
(2004)
Nat Immunol
, vol.5
, pp. 738-743
-
-
Hope, K.J.1
Jin, L.2
Dick, J.E.3
-
14
-
-
79952092993
-
Leukemia stem cells and microenvironment: Biology and therapeutic targeting
-
21220598
-
Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591-9.
-
(2011)
J Clin Oncol
, vol.29
, pp. 591-599
-
-
Konopleva, M.Y.1
Jordan, C.T.2
-
15
-
-
78149470597
-
Insights into the stem cells of chronic myeloid leukemia
-
1:CAS:528:DC%2BC3cXhtl2gt7vF 20861912
-
Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010;24:1823-33.
-
(2010)
Leukemia
, vol.24
, pp. 1823-1833
-
-
Sloma, I.1
Jiang, X.2
Eaves, A.C.3
Eaves, C.J.4
-
16
-
-
77953460959
-
Acute myeloid leukemia stem cells: Seek and destroy
-
21082958
-
Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: seek and destroy. Expert Rev Hematol. 2009;2:663-72.
-
(2009)
Expert Rev Hematol
, vol.2
, pp. 663-672
-
-
Roboz, G.J.1
Guzman, M.2
-
17
-
-
0035254540
-
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
-
1:CAS:528:DC%2BD3MXhtVSjsbs%3D 11157490
-
Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, Laird C, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood. 2001;97:720-8.
-
(2001)
Blood
, vol.97
, pp. 720-728
-
-
Holyoake, T.L.1
Jiang, X.2
Jorgensen, H.G.3
Graham, S.4
Alcorn, M.J.5
Laird, C.6
-
18
-
-
63549121688
-
Chronic myelogenous leukemia stem cells: What's new?
-
20425417
-
Copland M. Chronic myelogenous leukemia stem cells: what's new? Curr Hematol Malig Rep. 2009;4:66-73.
-
(2009)
Curr Hematol Malig Rep
, vol.4
, pp. 66-73
-
-
Copland, M.1
-
19
-
-
77956178360
-
EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer
-
3176718 1:CAS:528:DC%2BC3cXntVSrur0%3D 20531305
-
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741-51.
-
(2010)
Oncogene
, vol.29
, pp. 4741-4751
-
-
Singh, A.1
Settleman, J.2
-
20
-
-
23044514578
-
Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis
-
1:CAS:528:DC%2BD2MXpslSlsLo%3D 16027397
-
Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45:872-7.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 872-877
-
-
Donnenberg, V.S.1
Donnenberg, A.D.2
-
21
-
-
16844368698
-
Tumour stem cells and drug resistance
-
1:CAS:528:DC%2BD2MXivVarsL4%3D 15803154
-
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 275-284
-
-
Dean, M.1
Fojo, T.2
Bates, S.3
-
22
-
-
34247555482
-
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
-
1:CAS:528:DC%2BD2sXksFeltL4%3D 17330101
-
Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21:926-35.
-
(2007)
Leukemia
, vol.21
, pp. 926-935
-
-
Jiang, X.1
Zhao, Y.2
Smith, C.3
Gasparetto, M.4
Turhan, A.5
Eaves, A.6
-
23
-
-
33845664398
-
Primitive, quiescent and difficult to kill: The role of non-proliferating stem cells in chronic myeloid leukemia
-
1:CAS:528:DC%2BD2sXksVOit7w%3D 17172863
-
Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle. 2006;5:2862-6.
-
(2006)
Cell Cycle
, vol.5
, pp. 2862-2866
-
-
Barnes, D.J.1
Melo, J.V.2
-
24
-
-
84907997640
-
Mutation position within evolutionary subclonal architecture in AML
-
1:CAS:528:DC%2BC2cXhslGrs7bL 25311740
-
Welch JS. Mutation position within evolutionary subclonal architecture in AML. Semin Hematol. 2014;51:273-83.
-
(2014)
Semin Hematol
, vol.51
, pp. 273-283
-
-
Welch, J.S.1
-
25
-
-
84924736520
-
Side population cells and drug resistance in breast cancer
-
doi:10.3892/mmr.2015.3291
-
Wang M, Wang Y, Zhong J. Side population cells and drug resistance in breast cancer. Mol Med Rep. 2015;doi:10.3892/mmr.2015.3291.
-
(2015)
Mol Med Rep.
-
-
Wang, M.1
Wang, Y.2
Zhong, J.3
-
26
-
-
84655169099
-
Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia
-
1:CAS:528:DC%2BC38XhtVChsA%3D%3D 21955823
-
Preuner S, Mitterbauer G, Mannhalter C, Herndlhofer S, Sperr WR, Valent P, et al. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. Eur J Cancer. 2012;48:233-6.
-
(2012)
Eur J Cancer
, vol.48
, pp. 233-236
-
-
Preuner, S.1
Mitterbauer, G.2
Mannhalter, C.3
Herndlhofer, S.4
Sperr, W.R.5
Valent, P.6
-
27
-
-
38349165576
-
Identification of cells initiating human melanomas
-
3660705 1:CAS:528:DC%2BD1cXnt1Gisg%3D%3D 18202660
-
Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345-9.
-
(2008)
Nature
, vol.451
, pp. 345-349
-
-
Schatton, T.1
Murphy, G.F.2
Frank, N.Y.3
Yamaura, K.4
Waaga-Gasser, A.M.5
Gasser, M.6
-
28
-
-
78951476130
-
Targeting of leukemia-initiating cells to develop curative drug therapies: Straightforward but nontrivial concept
-
1:CAS:528:DC%2BC3MXhsVelsLg%3D 21062243
-
Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2011;11(1):56-71.
-
(2011)
Curr Cancer Drug Targets
, vol.11
, Issue.1
, pp. 56-71
-
-
Valent, P.1
-
29
-
-
74949090309
-
The therapeutic promise of the cancer stem cell concept
-
2798700 1:CAS:528:DC%2BC3cXislWgtw%3D%3D 20051635
-
Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120:41-50.
-
(2010)
J Clin Invest
, vol.120
, pp. 41-50
-
-
Frank, N.Y.1
Schatton, T.2
Frank, M.H.3
-
30
-
-
63449116272
-
Cancer stem cells: The emerging challenge of drug targeting
-
1:CAS:528:DC%2BD1MXjsFGqsLw%3D 19199913
-
Besancon R, Valsesia-Wittmann S, Puisieux A, de Fromentel CC, Maguer-Satta V. Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem. 2009;16:394-416.
-
(2009)
Curr Med Chem
, vol.16
, pp. 394-416
-
-
Besancon, R.1
Valsesia-Wittmann, S.2
Puisieux, A.3
De Fromentel, C.C.4
Maguer-Satta, V.5
-
31
-
-
34948837444
-
Selective targeting of cancer stem cells: A new concept in cancer therapeutics
-
1:CAS:528:DC%2BD2sXht1yitb%2FJ 17896836
-
Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs. 2007;21:299-310.
-
(2007)
BioDrugs
, vol.21
, pp. 299-310
-
-
Korkaya, H.1
Wicha, M.S.2
-
32
-
-
0030789242
-
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
-
1:CAS:528:DyaK2sXkt1GrtLY%3D 9212098
-
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7.
-
(1997)
Nat Med
, vol.3
, pp. 730-737
-
-
Bonnet, D.1
Dick, J.E.2
-
33
-
-
0028091194
-
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
-
1:STN:280:DyaK2c7ltVKrsg%3D%3D 7509044
-
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-8.
-
(1994)
Nature
, vol.367
, pp. 645-648
-
-
Lapidot, T.1
Sirard, C.2
Vormoor, J.3
Murdoch, B.4
Hoang, T.5
Caceres-Cortes, J.6
-
34
-
-
79954617310
-
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth
-
1:CAS:528:DC%2BC3MXkslWjsb4%3D 21393506
-
Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011;71:3098-109.
-
(2011)
Cancer Res
, vol.71
, pp. 3098-3109
-
-
Civenni, G.1
Walter, A.2
Kobert, N.3
Mihic-Probst, D.4
Zipser, M.5
Belloni, B.6
-
35
-
-
57549093082
-
Creation of "humanized" mice to study human immunity
-
18491294
-
Pearson T, Greiner DL, Shultz LD. Creation of "humanized" mice to study human immunity. Curr Protoc Immunol. 2008;15(15):21.
-
(2008)
Curr Protoc Immunol
, vol.15
, Issue.15
, pp. 21
-
-
Pearson, T.1
Greiner, D.L.2
Shultz, L.D.3
-
36
-
-
44449085902
-
The differentiative and regenerative properties of human hematopoietic stem/progenitor cells in NOD-SCID/IL2rgamma(null) mice
-
1:CAS:528:DC%2BD1cXosFGnsrs%3D 18481454
-
Ishikawa F, Saito Y, Yoshida S, Harada M, Shultz LD. The differentiative and regenerative properties of human hematopoietic stem/progenitor cells in NOD-SCID/IL2rgamma(null) mice. Curr Top Microbiol Immunol. 2008;324:87-94.
-
(2008)
Curr Top Microbiol Immunol
, vol.324
, pp. 87-94
-
-
Ishikawa, F.1
Saito, Y.2
Yoshida, S.3
Harada, M.4
Shultz, L.D.5
-
37
-
-
57349143739
-
Efficient tumour formation by single human melanoma cells
-
2597380 1:CAS:528:DC%2BD1cXhsVGlur7K 19052619
-
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593-8.
-
(2008)
Nature
, vol.456
, pp. 593-598
-
-
Quintana, E.1
Shackleton, M.2
Sabel, M.S.3
Fullen, D.R.4
Johnson, T.M.5
Morrison, S.J.6
-
38
-
-
50949090415
-
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
-
1:CAS:528:DC%2BD1cXpsVajurg%3D 18523148
-
Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008;112:568-75.
-
(2008)
Blood
, vol.112
, pp. 568-575
-
-
Taussig, D.C.1
Miraki-Moud, F.2
Anjos-Afonso, F.3
Pearce, D.J.4
Allen, K.5
Ridler, C.6
-
39
-
-
34548455927
-
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer
-
1:CAS:528:DC%2BD2sXhtFagu7vN 18371365
-
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23.
-
(2007)
Cell Stem Cell
, vol.1
, pp. 313-323
-
-
Hermann, P.C.1
Huber, S.L.2
Herrler, T.3
Aicher, A.4
Ellwart, J.W.5
Guba, M.6
-
40
-
-
0037388204
-
Prospective identification of tumorigenic breast cancer cells
-
153034 1:CAS:528:DC%2BD3sXivFSqtbs%3D 12629218
-
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 3983-3988
-
-
Al-Hajj, M.1
Wicha, M.S.2
Benito-Hernandez, A.3
Morrison, S.J.4
Clarke, M.F.5
-
41
-
-
33845317573
-
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
-
1:CAS:528:DC%2BD28Xht1OntbzP 17051156
-
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-60.
-
(2006)
Nature
, vol.444
, pp. 756-760
-
-
Bao, S.1
Wu, Q.2
McLendon, R.E.3
Hao, Y.4
Shi, Q.5
Hjelmeland, A.B.6
-
42
-
-
9244241576
-
Identification of human brain tumour initiating cells
-
1:CAS:528:DC%2BD2cXpvVCjtbY%3D 15549107
-
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
-
(2004)
Nature
, vol.432
, pp. 396-401
-
-
Singh, S.K.1
Hawkins, C.2
Clarke, I.D.3
Squire, J.A.4
Bayani, J.5
Hide, T.6
-
43
-
-
33847052127
-
Identification of pancreatic cancer stem cells
-
1:CAS:528:DC%2BD2sXht1yns70%3D 17283135
-
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-7.
-
(2007)
Cancer Res
, vol.67
, pp. 1030-1037
-
-
Li, C.1
Heidt, D.G.2
Dalerba, P.3
Burant, C.F.4
Zhang, L.5
Adsay, V.6
-
44
-
-
38549139140
-
Significance of CD90+ cancer stem cells in human liver cancer
-
1:CAS:528:DC%2BD1cXitFWrs7c%3D 18242515
-
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153-66.
-
(2008)
Cancer Cell
, vol.13
, pp. 153-166
-
-
Yang, Z.F.1
Ho, D.W.2
Ng, M.N.3
Lau, C.K.4
Yu, W.C.5
Ngai, P.6
-
45
-
-
35948984135
-
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
-
1:CAS:528:DC%2BD2sXht1Oru7zP 17952057
-
Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315-21.
-
(2007)
Nat Biotechnol
, vol.25
, pp. 1315-1321
-
-
Ishikawa, F.1
Yoshida, S.2
Saito, Y.3
Hijikata, A.4
Kitamura, H.5
Tanaka, S.6
-
46
-
-
33846100356
-
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
-
17122772
-
O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-10.
-
(2007)
Nature
, vol.445
, pp. 106-110
-
-
O'Brien, C.A.1
Pollett, A.2
Gallinger, S.3
Dick, J.E.4
-
47
-
-
33846095137
-
Identification and expansion of human colon-cancer-initiating cells
-
1:CAS:528:DC%2BD2sXhsFOmug%3D%3D 17122771
-
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-5.
-
(2007)
Nature
, vol.445
, pp. 111-115
-
-
Ricci-Vitiani, L.1
Lombardi, D.G.2
Pilozzi, E.3
Biffoni, M.4
Todaro, M.5
Peschle, C.6
-
48
-
-
79955053058
-
Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: Origin from neoplastic yet 'pre-leukemic' stem cells?
-
21463112
-
Bohm A, Herrmann H, Mitterbauer-Hohendanner G, Hauswirth AW, Rabitsch W, Mitterbauer M, et al. Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet 'pre-leukemic' stem cells? Leuk Lymphoma. 2011;52:842-8.
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 842-848
-
-
Bohm, A.1
Herrmann, H.2
Mitterbauer-Hohendanner, G.3
Hauswirth, A.W.4
Rabitsch, W.5
Mitterbauer, M.6
-
49
-
-
0037948854
-
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
-
196056 1:CAS:528:DC%2BD3sXktVGmt7s%3D 12756227
-
Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253-70.
-
(2003)
Genes Dev
, vol.17
, pp. 1253-1270
-
-
Dontu, G.1
Abdallah, W.M.2
Foley, J.M.3
Jackson, K.W.4
Clarke, M.F.5
Kawamura, M.J.6
-
50
-
-
27144557960
-
A tumorigenic subpopulation with stem cell properties in melanomas
-
1:CAS:528:DC%2BD2MXhtFWmu7zI 16230395
-
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65:9328-37.
-
(2005)
Cancer Res
, vol.65
, pp. 9328-9337
-
-
Fang, D.1
Nguyen, T.K.2
Leishear, K.3
Finko, R.4
Kulp, A.N.5
Hotz, S.6
-
51
-
-
0017694555
-
Conditions controlling the proliferation of haemopoietic stem cells in vitro
-
1:STN:280:DyaE2s7ovVSnsQ%3D%3D 301143
-
Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol. 1977;91:335-44.
-
(1977)
J Cell Physiol
, vol.91
, pp. 335-344
-
-
Dexter, T.M.1
Allen, T.D.2
Lajtha, L.G.3
-
52
-
-
0344735881
-
Cancerous stem cells can arise from pediatric brain tumors
-
299944 1:CAS:528:DC%2BD3sXpvFaqu70%3D 14645703
-
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100:15178-83.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 15178-15183
-
-
Hemmati, H.D.1
Nakano, I.2
Lazareff, J.A.3
Masterman-Smith, M.4
Geschwind, D.H.5
Bronner-Fraser, M.6
-
53
-
-
51649111430
-
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity
-
2533206 1:CAS:528:DC%2BD1cXhtFChs7rP 18765800
-
Vermeulen L, Todaro M, de Sousa MF, Sprick MR, Kemper K, Perez Alea M, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A. 2008;105:13427-32.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 13427-13432
-
-
Vermeulen, L.1
Todaro, M.2
De Sousa, M.F.3
Sprick, M.R.4
Kemper, K.5
Perez Alea, M.6
-
54
-
-
84920128407
-
Characterization of breast cancer DNA content profiles as a prognostic tool
-
1:STN:280:DC%2BC2MvhsFWgtQ%3D%3D 25537213
-
Gerashchenko BI, Huna A, Erenpreisa J. Characterization of breast cancer DNA content profiles as a prognostic tool. Exp Oncol. 2014;36:219-25.
-
(2014)
Exp Oncol
, vol.36
, pp. 219-225
-
-
Gerashchenko, B.I.1
Huna, A.2
Erenpreisa, J.3
-
55
-
-
73649139235
-
Side population and cancer stem cells: Therapeutic implications
-
1:CAS:528:DC%2BC3cXnvFygtg%3D%3D 19523754
-
Moserle L, Ghisi M, Amadori A, Indraccolo S. Side population and cancer stem cells: therapeutic implications. Cancer Lett. 2010;288:1-9.
-
(2010)
Cancer Lett
, vol.288
, pp. 1-9
-
-
Moserle, L.1
Ghisi, M.2
Amadori, A.3
Indraccolo, S.4
-
56
-
-
77950021915
-
Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1
-
1:CAS:528:DC%2BC3cXksVaru7Y%3D 19913993
-
Fukaya R, Ohta S, Yamaguchi M, Fujii H, Kawakami Y, Kawase T, et al. Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Lett. 2010;291:150-7.
-
(2010)
Cancer Lett
, vol.291
, pp. 150-157
-
-
Fukaya, R.1
Ohta, S.2
Yamaguchi, M.3
Fujii, H.4
Kawakami, Y.5
Kawase, T.6
-
57
-
-
70349941243
-
Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas
-
2768447 1:CAS:528:DC%2BD1MXht1GntbvP 19826427
-
Murase M, Kano M, Tsukahara T, Takahashi A, Torigoe T, Kawaguchi S, et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer. 2009;101:1425-32.
-
(2009)
Br J Cancer
, vol.101
, pp. 1425-1432
-
-
Murase, M.1
Kano, M.2
Tsukahara, T.3
Takahashi, A.4
Torigoe, T.5
Kawaguchi, S.6
-
58
-
-
75949101677
-
ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome
-
3552330 1:CAS:528:DC%2BC3cXht1Kqs7g%3D 20010854
-
Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest. 2010;90:234-44.
-
(2010)
Lab Invest
, vol.90
, pp. 234-244
-
-
Li, T.1
Su, Y.2
Mei, Y.3
Leng, Q.4
Leng, B.5
Liu, Z.6
-
59
-
-
70449413732
-
Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes
-
1:CAS:528:DC%2BD1MXhsVentrzO 19819294
-
Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P, Eckstein V, et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol. 2009;37:1423-34.
-
(2009)
Exp Hematol
, vol.37
, pp. 1423-1434
-
-
Ran, D.1
Schubert, M.2
Pietsch, L.3
Taubert, I.4
Wuchter, P.5
Eckstein, V.6
-
60
-
-
67349209852
-
Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer
-
1:CAS:528:DC%2BD1MXnt1Kjtb4%3D 19450560
-
Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385:307-13.
-
(2009)
Biochem Biophys Res Commun
, vol.385
, pp. 307-313
-
-
Chen, Y.C.1
Chen, Y.W.2
Hsu, H.S.3
Tseng, L.M.4
Huang, P.I.5
Lu, K.H.6
-
61
-
-
67349191354
-
Aldehyde dehydrogenase as a marker for stem cells
-
1:CAS:528:DC%2BD1cXhsVKhsrrJ 19075754
-
Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther. 2008;3:237-46.
-
(2008)
Curr Stem Cell Res Ther
, vol.3
, pp. 237-246
-
-
Moreb, J.S.1
-
62
-
-
33644826473
-
Roots and stems: Stem cells in cancer
-
1:CAS:528:DC%2BD28XitVGntL8%3D 16520777
-
Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med. 2006;12:296-300.
-
(2006)
Nat Med
, vol.12
, pp. 296-300
-
-
Polyak, K.1
Hahn, W.C.2
-
63
-
-
55749107812
-
The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases
-
2574516 1:CAS:528:DC%2BD1cXhtlCntr3F 18948588
-
Weissman IL, Shizuru JA. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood. 2008;112:3543-53.
-
(2008)
Blood
, vol.112
, pp. 3543-3553
-
-
Weissman, I.L.1
Shizuru, J.A.2
-
64
-
-
30644481023
-
Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies
-
1:CAS:528:DC%2BD2MXht1Kntb3P 16321850
-
Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, et al. Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk Lymphoma. 2006;47:207-22.
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 207-222
-
-
Florian, S.1
Sonneck, K.2
Hauswirth, A.W.3
Krauth, M.T.4
Schernthaner, G.H.5
Sperr, W.R.6
-
65
-
-
58049211689
-
Identification of a small subpopulation of candidate leukemia initiating cells in the side population (SP) of patients with acute myeloid leukemia
-
19096043
-
Moshaver B, van Rhenen A, Kelder A, van der Pol M, Terwijn M, Bachas C, et al. Identification of a small subpopulation of candidate leukemia initiating cells in the side population (SP) of patients with acute myeloid leukemia. Stem Cells. 2008;26(12):3059-67.
-
(2008)
Stem Cells
, vol.26
, Issue.12
, pp. 3059-3067
-
-
Moshaver, B.1
Van Rhenen, A.2
Kelder, A.3
Van Der Pol, M.4
Terwijn, M.5
Bachas, C.6
-
66
-
-
0030988803
-
Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo
-
1:CAS:528:DyaK2sXivVOnt7c%3D 9129012
-
Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:3104-12.
-
(1997)
Blood
, vol.89
, pp. 3104-3112
-
-
Blair, A.1
Hogge, D.E.2
Ailles, L.E.3
Lansdorp, P.M.4
Sutherland, H.J.5
-
67
-
-
34948839959
-
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
-
17609428
-
van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659-66.
-
(2007)
Blood
, vol.110
, pp. 2659-2666
-
-
Van Rhenen, A.1
Van Dongen, G.A.2
Kelder, A.3
Rombouts, E.J.4
Feller, N.5
Moshaver, B.6
-
68
-
-
34547415968
-
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
-
1904175 1:CAS:528:DC%2BD2sXnsV2ks74%3D 17576927
-
Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104:11008-13.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 11008-11013
-
-
Hosen, N.1
Park, C.Y.2
Tatsumi, N.3
Oji, Y.4
Sugiyama, H.5
Gramatzki, M.6
-
69
-
-
0033815950
-
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
-
1:CAS:528:DC%2BD3cXnslWgsbY%3D 11021753
-
Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-84.
-
(2000)
Leukemia
, vol.14
, pp. 1777-1784
-
-
Jordan, C.T.1
Upchurch, D.2
Szilvassy, S.J.3
Guzman, M.L.4
Howard, D.S.5
Pettigrew, A.L.6
-
70
-
-
0025329430
-
Expression of the CD34 gene in vascular endothelial cells
-
1:CAS:528:DyaK3cXkslKisr4%3D 1693532
-
Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood. 1990;75:2417-26.
-
(1990)
Blood
, vol.75
, pp. 2417-2426
-
-
Fina, L.1
Molgaard, H.V.2
Robertson, D.3
Bradley, N.J.4
Monaghan, P.5
Delia, D.6
-
71
-
-
12144257058
-
Kit as a human oncogenic tyrosine kinase
-
1:CAS:528:DC%2BD2MXot1agsQ%3D%3D 15583854
-
Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004;61:2924-31.
-
(2004)
Cell Mol Life Sci
, vol.61
, pp. 2924-2931
-
-
Kitamura, Y.1
Hirotab, S.2
-
72
-
-
33749515476
-
Targeting of CD44 eradicates human acute myeloid leukemic stem cells
-
16998484
-
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12:1167-74.
-
(2006)
Nat Med
, vol.12
, pp. 1167-1174
-
-
Jin, L.1
Hope, K.J.2
Zhai, Q.3
Smadja-Joffe, F.4
Dick, J.E.5
-
73
-
-
67650632683
-
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells
-
2726837 1:CAS:528:DC%2BD1MXhtVSgtr3N 19632179
-
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs Jr KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286-99.
-
(2009)
Cell
, vol.138
, pp. 286-299
-
-
Majeti, R.1
Chao, M.P.2
Alizadeh, A.A.3
Pang, W.W.4
Jaiswal, S.5
Gibbs, Jr.K.D.6
-
74
-
-
44149121701
-
CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells
-
2386794 18433506
-
Kim JB, Ko E, Han W, Lee JE, Lee KM, Shin I, et al. CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells. BMC Cancer. 2008;8:118.
-
(2008)
BMC Cancer
, vol.8
, pp. 118
-
-
Kim, J.B.1
Ko, E.2
Han, W.3
Lee, J.E.4
Lee, K.M.5
Shin, I.6
-
75
-
-
77749294821
-
Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells
-
Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2:17ra19.
-
(2010)
Sci Transl Med
, vol.2
, pp. 17ra19
-
-
Saito, Y.1
Kitamura, H.2
Hijikata, A.3
Tomizawa-Murasawa, M.4
Tanaka, S.5
Takagi, S.6
-
76
-
-
28844456971
-
Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia
-
1895250 1:CAS:528:DC%2BD2MXhtlaltrzK 16131573
-
Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106:4086-92.
-
(2005)
Blood
, vol.106
, pp. 4086-4092
-
-
Taussig, D.C.1
Pearce, D.J.2
Simpson, C.3
Rohatiner, A.Z.4
Lister, T.A.5
Kelly, G.6
-
77
-
-
84903839705
-
Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML
-
1:CAS:528:DC%2BC2cXhtVKksrvL 24799522
-
Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, et al. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML. Clin Cancer Res. 2014;20(13):3589-602.
-
(2014)
Clin Cancer Res
, vol.20
, Issue.13
, pp. 3589-3602
-
-
Blatt, K.1
Herrmann, H.2
Hoermann, G.3
Willmann, M.4
Cerny-Reiterer, S.5
Sadovnik, I.6
-
78
-
-
77950451485
-
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction
-
2837317 1:CAS:528:DC%2BC3cXhtFensbbJ 20053758
-
Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010;115:1976-84.
-
(2010)
Blood
, vol.115
, pp. 1976-1984
-
-
Taussig, D.C.1
Vargaftig, J.2
Miraki-Moud, F.3
Griessinger, E.4
Sharrock, K.5
Luke, T.6
-
79
-
-
0036659925
-
Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8
-
1:CAS:528:DC%2BD38XltF2rtrw%3D 12070035
-
Nilsson L, Astrand-Grundstrom I, Anderson K, Arvidsson I, Hokland P, Bryder D, et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002;100:259-67.
-
(2002)
Blood
, vol.100
, pp. 259-267
-
-
Nilsson, L.1
Astrand-Grundstrom, I.2
Anderson, K.3
Arvidsson, I.4
Hokland, P.5
Bryder, D.6
-
80
-
-
84868106325
-
Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes
-
23086775
-
De Smet D, Trullemans F, Jochmans K, Renmans W, Smet L, Heylen O, et al. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes. Am J Clin Pathol. 2012;138:732-43.
-
(2012)
Am J Clin Pathol
, vol.138
, pp. 732-743
-
-
De Smet, D.1
Trullemans, F.2
Jochmans, K.3
Renmans, W.4
Smet, L.5
Heylen, O.6
-
81
-
-
0034665776
-
Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: Evidence for involvement at the hematopoietic stem cell level
-
1:CAS:528:DC%2BD3cXms1Chsrk%3D 10979941
-
Nilsson L, Astrand-Grundstrom I, Arvidsson I, Jacobsson B, Hellstrom-Lindberg E, Hast R, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 2000;96:2012-21.
-
(2000)
Blood
, vol.96
, pp. 2012-2021
-
-
Nilsson, L.1
Astrand-Grundstrom, I.2
Arvidsson, I.3
Jacobsson, B.4
Hellstrom-Lindberg, E.5
Hast, R.6
-
82
-
-
33646546386
-
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
-
1434515 1:CAS:528:DC%2BD28XktFamsL8%3D 16603627
-
Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006;103:6224-9.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 6224-6229
-
-
Jamieson, C.H.1
Gotlib, J.2
Durocher, J.A.3
Chao, M.P.4
Mariappan, M.R.5
Lay, M.6
-
83
-
-
84899109507
-
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells
-
1:CAS:528:DC%2BC2cXntVejtLk%3D 24574458
-
Kobayashi CI, Takubo K, Kobayashi H, Nakamura-Ishizu A, Honda H, Kataoka K, et al. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood. 2014;123:2540-9.
-
(2014)
Blood
, vol.123
, pp. 2540-2549
-
-
Kobayashi, C.I.1
Takubo, K.2
Kobayashi, H.3
Nakamura-Ishizu, A.4
Honda, H.5
Kataoka, K.6
-
84
-
-
84902661806
-
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
-
1:CAS:528:DC%2BC2cXhtFWhu7nL 24778155
-
Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123(25):3951-62.
-
(2014)
Blood
, vol.123
, Issue.25
, pp. 3951-3962
-
-
Herrmann, H.1
Sadovnik, I.2
Cerny-Reiterer, S.3
Rulicke, T.4
Stefanzl, G.5
Willmann, M.6
-
85
-
-
84856481430
-
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin
-
3269481 1:CAS:528:DC%2BC38XhslSksLjM 21993666
-
Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, et al. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica. 2012;97:219-26.
-
(2012)
Haematologica
, vol.97
, pp. 219-226
-
-
Herrmann, H.1
Cerny-Reiterer, S.2
Gleixner, K.V.3
Blatt, K.4
Herndlhofer, S.5
Rabitsch, W.6
-
86
-
-
84899137486
-
Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells
-
1:CAS:528:DC%2BC2cXjs1ygu78%3D 24363400
-
Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, et al. Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123:1218-28.
-
(2014)
Blood
, vol.123
, pp. 1218-1228
-
-
Nievergall, E.1
Ramshaw, H.S.2
Yong, A.S.3
Biondo, M.4
Busfield, S.J.5
Vairo, G.6
-
87
-
-
77958004008
-
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein
-
2941341 1:CAS:528:DC%2BC3cXhtF2gsb7J 20805474
-
Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A. 2010;107:16280-5.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 16280-16285
-
-
Jaras, M.1
Johnels, P.2
Hansen, N.3
Agerstam, H.4
Tsapogas, P.5
Rissler, M.6
-
88
-
-
0034141934
-
A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia
-
1:CAS:528:DC%2BD3cXotV2nsg%3D%3D 10648416
-
Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood. 2000;95:1007-13.
-
(2000)
Blood
, vol.95
, pp. 1007-1013
-
-
Cobaleda, C.1
Gutierrez-Cianca, N.2
Perez-Losada, J.3
Flores, T.4
Garcia-Sanz, R.5
Gonzalez, M.6
-
89
-
-
45149133254
-
CD34∈+∈CD38∈+∈CD19+ as well as CD34∈+∈CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL
-
1:CAS:528:DC%2BD1cXntVCjtbc%3D 18418410
-
Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M, et al. CD34∈+∈CD38∈+∈CD19+ as well as CD34∈+∈CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia. 2008;22:1207-13.
-
(2008)
Leukemia
, vol.22
, pp. 1207-1213
-
-
Kong, Y.1
Yoshida, S.2
Saito, Y.3
Doi, T.4
Nagatoshi, Y.5
Fukata, M.6
-
90
-
-
84895828705
-
CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells
-
1:CAS:528:DC%2BC3sXhvVyktLjN 24202404
-
Rossi FM, Zucchetto A, Tissino E, Dal Bo M, Bomben R, Caldana C, et al. CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells. Leukemia. 2014;28:705-8.
-
(2014)
Leukemia
, vol.28
, pp. 705-708
-
-
Rossi, F.M.1
Zucchetto, A.2
Tissino, E.3
Dal Bo, M.4
Bomben, R.5
Caldana, C.6
-
91
-
-
38549132452
-
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
-
2603142 1:CAS:528:DC%2BD1cXoslSi 18172311
-
Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68:190-7.
-
(2008)
Cancer Res
, vol.68
, pp. 190-197
-
-
Matsui, W.1
Wang, Q.2
Barber, J.P.3
Brennan, S.4
Smith, B.D.5
Borrello, I.6
-
92
-
-
77953163539
-
CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer
-
4129519 1:CAS:528:DC%2BC3cXmslWgtLk%3D 20484027
-
Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010;70:4624-33.
-
(2010)
Cancer Res
, vol.70
, pp. 4624-4633
-
-
Meyer, M.J.1
Fleming, J.M.2
Lin, A.F.3
Hussnain, S.A.4
Ginsburg, E.5
Vonderhaar, B.K.6
-
93
-
-
84880270290
-
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
-
1:CAS:528:DC%2BC3sXmt1WisLw%3D 23609047
-
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539-44.
-
(2013)
Nat Biotechnol
, vol.31
, pp. 539-544
-
-
Baccelli, I.1
Schneeweiss, A.2
Riethdorf, S.3
Stenzinger, A.4
Schillert, A.5
Vogel, V.6
-
94
-
-
80054772926
-
Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research
-
1:CAS:528:DC%2BC3MXhtlShtb%2FI 21448722
-
Han ME, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE, et al. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci. 2011;68:3589-605.
-
(2011)
Cell Mol Life Sci
, vol.68
, pp. 3589-3605
-
-
Han, M.E.1
Jeon, T.Y.2
Hwang, S.H.3
Lee, Y.S.4
Kim, H.J.5
Shim, H.E.6
-
95
-
-
84883155193
-
CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors
-
3756075 1:CAS:528:DC%2BC3sXhsVagtL7M 24015244
-
Fukamachi H, Seol HS, Shimada S, Funasaka C, Baba K, Kim JH, et al. CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors. PLoS One. 2013;8:e72438.
-
(2013)
PLoS One
, vol.8
, pp. 72438
-
-
Fukamachi, H.1
Seol, H.S.2
Shimada, S.3
Funasaka, C.4
Baba, K.5
Kim, J.H.6
-
96
-
-
84856963775
-
Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype
-
1:CAS:528:DC%2BC3MXos1OmtL0%3D 21743497
-
Jiang J, Zhang Y, Chuai S, Wang Z, Zheng D, Xu F, et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene. 2012;31:671-82.
-
(2012)
Oncogene
, vol.31
, pp. 671-682
-
-
Jiang, J.1
Zhang, Y.2
Chuai, S.3
Wang, Z.4
Zheng, D.5
Xu, F.6
-
97
-
-
84892403903
-
Distribution of LGR5+ cells and associated implications during the early stage of gastric tumorigenesis
-
3858308 24340024
-
Jang BG, Lee BL, Kim WH. Distribution of LGR5+ cells and associated implications during the early stage of gastric tumorigenesis. PLoS One. 2013;8:e82390.
-
(2013)
PLoS One
, vol.8
, pp. 82390
-
-
Jang, B.G.1
Lee, B.L.2
Kim, W.H.3
-
98
-
-
66149175569
-
Identification of gastric cancer stem cells using the cell surface marker CD44
-
2746367 1:CAS:528:DC%2BD1MXnsF2rs70%3D 19415765
-
Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27:1006-20.
-
(2009)
Stem Cells
, vol.27
, pp. 1006-1020
-
-
Takaishi, S.1
Okumura, T.2
Tu, S.3
Wang, S.S.4
Shibata, W.5
Vigneshwaran, R.6
-
99
-
-
34547193404
-
Phenotypic characterization of human colorectal cancer stem cells
-
1891215 1:CAS:528:DC%2BD2sXmvVCntLw%3D 17548814
-
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104:10158-63.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 10158-10163
-
-
Dalerba, P.1
Dylla, S.J.2
Park, I.K.3
Liu, R.4
Wang, X.5
Cho, R.W.6
-
100
-
-
84879632446
-
CD49f-positive cell population efficiently enriches colon cancer-initiating cells
-
23708747
-
Haraguchi N, Ishii H, Mimori K, Ohta K, Uemura M, Nishimura J, et al. CD49f-positive cell population efficiently enriches colon cancer-initiating cells. Int J Oncol. 2013;43:425-30.
-
(2013)
Int J Oncol
, vol.43
, pp. 425-430
-
-
Haraguchi, N.1
Ishii, H.2
Mimori, K.3
Ohta, K.4
Uemura, M.5
Nishimura, J.6
-
101
-
-
35548974423
-
Identification of stem cells in small intestine and colon by marker gene Lgr5
-
1:CAS:528:DC%2BD2sXht1Wgtr3E 17934449
-
Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007;449:1003-7.
-
(2007)
Nature
, vol.449
, pp. 1003-1007
-
-
Barker, N.1
Van Es, J.H.2
Kuipers, J.3
Kujala, P.4
Van Den Born, M.5
Cozijnsen, M.6
-
102
-
-
39449088496
-
Identification and expansion of the tumorigenic lung cancer stem cell population
-
1:CAS:528:DC%2BD1cXitVOlsLo%3D 18049477
-
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504-14.
-
(2008)
Cell Death Differ
, vol.15
, pp. 504-514
-
-
Eramo, A.1
Lotti, F.2
Sette, G.3
Pilozzi, E.4
Biffoni, M.5
Di Virgilio, A.6
-
103
-
-
68749092099
-
The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer
-
19464919
-
Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009;36(3):446-53.
-
(2009)
Eur J Cardiothorac Surg
, vol.36
, Issue.3
, pp. 446-453
-
-
Tirino, V.1
Camerlingo, R.2
Franco, R.3
Malanga, D.4
La Rocca, A.5
Viglietto, G.6
-
104
-
-
60449087921
-
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features
-
2828822 1:CAS:528:DC%2BD1MXjslSju78%3D 19150350
-
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012-24.
-
(2009)
Gastroenterology
, vol.136
, pp. 1012-1024
-
-
Yamashita, T.1
Ji, J.2
Budhu, A.3
Forgues, M.4
Yang, W.5
Wang, H.Y.6
-
105
-
-
40749150740
-
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway
-
1:CAS:528:DC%2BD1cXjtFOnsbw%3D 17891174
-
Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27:1749-58.
-
(2008)
Oncogene
, vol.27
, pp. 1749-1758
-
-
Ma, S.1
Lee, T.K.2
Zheng, B.J.3
Chan, K.W.4
Guan, X.Y.5
-
106
-
-
84873396727
-
CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component
-
1:CAS:528:DC%2BC3sXivVSrt74%3D 23319191
-
Kahlert UD, Bender NO, Maciaczyk D, Bogiel T, Bar EE, Eberhart CG, et al. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component. Folia Neuropathol. 2012;50:357-68.
-
(2012)
Folia Neuropathol
, vol.50
, pp. 357-368
-
-
Kahlert, U.D.1
Bender, N.O.2
Maciaczyk, D.3
Bogiel, T.4
Bar, E.E.5
Eberhart, C.G.6
-
107
-
-
65349115320
-
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma
-
1:CAS:528:DC%2BD1MXlvVGjtLc%3D 19427293
-
Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4:440-52.
-
(2009)
Cell Stem Cell
, vol.4
, pp. 440-452
-
-
Son, M.J.1
Woolard, K.2
Nam, D.H.3
Lee, J.4
Fine, H.A.5
-
108
-
-
62449230721
-
Identification of cancer stem cells in Ewing's sarcoma
-
1:CAS:528:DC%2BD1MXisFSrtrY%3D 19208848
-
Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res. 2009;69:1776-81.
-
(2009)
Cancer Res
, vol.69
, pp. 1776-1781
-
-
Suva, M.L.1
Riggi, N.2
Stehle, J.C.3
Baumer, K.4
Tercier, S.5
Joseph, J.M.6
-
109
-
-
79957883579
-
Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo
-
1:CAS:528:DC%2BC3MXnsFyqtL4%3D 21385990
-
Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. Faseb J. 2011;25:2022-30.
-
(2011)
Faseb J
, vol.25
, pp. 2022-2030
-
-
Tirino, V.1
Desiderio, V.2
Paino, F.3
De Rosa, A.4
Papaccio, F.5
Fazioli, F.6
-
110
-
-
77953170540
-
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance
-
3139225 1:CAS:528:DC%2BC3cXmslWgtLs%3D 20460510
-
Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010;70:4602-12.
-
(2010)
Cancer Res
, vol.70
, pp. 4602-4612
-
-
Adhikari, A.S.1
Agarwal, N.2
Wood, B.M.3
Porretta, C.4
Ruiz, B.5
Pochampally, R.R.6
-
111
-
-
84902504045
-
CD271+ osteosarcoma cells display stem-like properties
-
4043643 24893164
-
Tian J, Li X, Si M, Liu T, Li J. CD271+ osteosarcoma cells display stem-like properties. PLoS One. 2014;9:e98549.
-
(2014)
PLoS One
, vol.9
, pp. 98549
-
-
Tian, J.1
Li, X.2
Si, M.3
Liu, T.4
Li, J.5
-
112
-
-
84857137036
-
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance
-
3289387 1:CAS:528:DC%2BC38XivFSjs7Y%3D 22308459
-
Meirelles K, Benedict LA, Dombkowski D, Pepin D, Preffer FI, Teixeira J, et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A. 2012;109:2358-63.
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 2358-2363
-
-
Meirelles, K.1
Benedict, L.A.2
Dombkowski, D.3
Pepin, D.4
Preffer, F.I.5
Teixeira, J.6
-
113
-
-
84873026180
-
Evaluation of characteristics of CD44∈+∈CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures
-
3565868 1:CAS:528:DC%2BC3sXjsVSiurs%3D 23368632
-
Chen J, Wang J, Chen D, Yang J, Yang C, Zhang Y, et al. Evaluation of characteristics of CD44∈+∈CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol. 2013;14:7.
-
(2013)
BMC Cell Biol
, vol.14
, pp. 7
-
-
Chen, J.1
Wang, J.2
Chen, D.3
Yang, J.4
Yang, C.5
Zhang, Y.6
-
114
-
-
73349125059
-
CD133 expression defines a tumor initiating cell population in primary human ovarian cancer
-
1:CAS:528:DC%2BC3cXhsVCqsbk%3D 19816957
-
Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27:2875-83.
-
(2009)
Stem Cells
, vol.27
, pp. 2875-2883
-
-
Curley, M.D.1
Therrien, V.A.2
Cummings, C.L.3
Sergent, P.A.4
Koulouris, C.R.5
Friel, A.M.6
-
115
-
-
84859722833
-
Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability
-
3326009 1:CAS:528:DC%2BC38Xmtlanur4%3D 22514625
-
Guo C, Liu H, Zhang BH, Cadaneanu RM, Mayle AM, Garraway IP. Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. PLoS One. 2012;7:e34219.
-
(2012)
PLoS One
, vol.7
, pp. 34219
-
-
Guo, C.1
Liu, H.2
Zhang, B.H.3
Cadaneanu, R.M.4
Mayle, A.M.5
Garraway, I.P.6
-
116
-
-
39449090031
-
CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis
-
2259168 1:CAS:528:DC%2BD1cXitVGhtbk%3D 18268494
-
Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98:756-65.
-
(2008)
Br J Cancer
, vol.98
, pp. 756-765
-
-
Hurt, E.M.1
Kawasaki, B.T.2
Klarmann, G.J.3
Thomas, S.B.4
Farrar, W.L.5
-
117
-
-
45549091414
-
Prostate cancer stem cells: A new target for therapy
-
18539965
-
Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 2008;26:2862-70.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2862-2870
-
-
Maitland, N.J.1
Collins, A.T.2
-
118
-
-
77954238710
-
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
-
2898751 1:CAS:528:DC%2BC3cXot1Wkurk%3D 20596026
-
Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466:133-7.
-
(2010)
Nature
, vol.466
, pp. 133-137
-
-
Boiko, A.D.1
Razorenova, O.V.2
Van De Rijn, M.3
Swetter, S.M.4
Johnson, D.L.5
Ly, D.P.6
-
119
-
-
84905454413
-
ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit
-
1:CAS:528:DC%2BC2cXht1GntrvN 24934811
-
Wilson BJ, Saab KR, Ma J, Schatton T, Putz P, Zhan Q, et al. ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res. 2014;74:4196-207.
-
(2014)
Cancer Res
, vol.74
, pp. 4196-4207
-
-
Wilson, B.J.1
Saab, K.R.2
Ma, J.3
Schatton, T.4
Putz, P.5
Zhan, Q.6
-
120
-
-
84900384946
-
Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R
-
3906015 24489649
-
Mirkina I, Hadzijusufovic E, Krepler C, Mikula M, Mechtcheriakova D, Strommer S, et al. Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R. PLoS One. 2014;9:e84417.
-
(2014)
PLoS One
, vol.9
, pp. 84417
-
-
Mirkina, I.1
Hadzijusufovic, E.2
Krepler, C.3
Mikula, M.4
Mechtcheriakova, D.5
Strommer, S.6
-
121
-
-
84862777784
-
Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5(+) stem cell
-
1:CAS:528:DC%2BC38Xjs1Whsb0%3D 22406745
-
Yui S, Nakamura T, Sato T, Nemoto Y, Mizutani T, Zheng X, et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5(+) stem cell. Nat Med. 2012;18:618-23.
-
(2012)
Nat Med
, vol.18
, pp. 618-623
-
-
Yui, S.1
Nakamura, T.2
Sato, T.3
Nemoto, Y.4
Mizutani, T.5
Zheng, X.6
-
122
-
-
84867917224
-
Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells
-
1:CAS:528:DC%2BC38XhvVWgsbnO 22969042
-
Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H, Medema JP. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells. 2012;30:2378-86.
-
(2012)
Stem Cells
, vol.30
, pp. 2378-2386
-
-
Kemper, K.1
Prasetyanti, P.R.2
De Lau, W.3
Rodermond, H.4
Clevers, H.5
Medema, J.P.6
-
123
-
-
36849078711
-
Let-7 regulates self renewal and tumorigenicity of breast cancer cells
-
1:CAS:528:DC%2BD1cXksFGgtQ%3D%3D 18083101
-
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131:1109-23.
-
(2007)
Cell
, vol.131
, pp. 1109-1123
-
-
Yu, F.1
Yao, H.2
Zhu, P.3
Zhang, X.4
Pan, Q.5
Gong, C.6
-
124
-
-
35848955428
-
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
-
2423808 1:CAS:528:DC%2BD2sXhsVahtrvF 18371393
-
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555-67.
-
(2007)
Cell Stem Cell
, vol.1
, pp. 555-567
-
-
Ginestier, C.1
Hur, M.H.2
Charafe-Jauffret, E.3
Monville, F.4
Dutcher, J.5
Brown, M.6
-
125
-
-
84863337646
-
Membrane-bound human SCF/KL promotes in vivo human hematopoietic engraftment and myeloid differentiation
-
3327455 1:CAS:528:DC%2BC38XkvFaltL8%3D 22279057
-
Takagi S, Saito Y, Hijikata A, Tanaka S, Watanabe T, Hasegawa T, et al. Membrane-bound human SCF/KL promotes in vivo human hematopoietic engraftment and myeloid differentiation. Blood. 2012;119:2768-77.
-
(2012)
Blood
, vol.119
, pp. 2768-2777
-
-
Takagi, S.1
Saito, Y.2
Hijikata, A.3
Tanaka, S.4
Watanabe, T.5
Hasegawa, T.6
-
126
-
-
78650950098
-
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice
-
3007135 1:CAS:528:DC%2BC3MXis1yltw%3D%3D 21157036
-
Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest. 2011;121:384-95.
-
(2011)
J Clin Invest
, vol.121
, pp. 384-395
-
-
Sarry, J.E.1
Murphy, K.2
Perry, R.3
Sanchez, P.V.4
Secreto, A.5
Keefer, C.6
-
127
-
-
0035555724
-
CD133 (AC133) expression on AML cells and progenitors
-
1:STN:280:DC%2BD383hs12itA%3D%3D 11953029
-
Vercauteren SM, Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy. 2001;3:449-59.
-
(2001)
Cytotherapy
, vol.3
, pp. 449-459
-
-
Vercauteren, S.M.1
Sutherland, H.J.2
-
128
-
-
84873474915
-
Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional, and Clinical Implications
-
1:CAS:528:DC%2BC3sXhvV2ksLo%3D 23345162
-
Valent P, Bonnet D, Wohrer S, Andreeff M, Copland M, Chomienne C, et al. Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional, and Clinical Implications. Cancer Res. 2013;73:1037-45.
-
(2013)
Cancer Res
, vol.73
, pp. 1037-1045
-
-
Valent, P.1
Bonnet, D.2
Wohrer, S.3
Andreeff, M.4
Copland, M.5
Chomienne, C.6
-
129
-
-
79956351015
-
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
-
3093533 1:CAS:528:DC%2BC3MXmsVSkur0%3D 21498687
-
Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011;108:7950-5.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 7950-7955
-
-
Chaffer, C.L.1
Brueckmann, I.2
Scheel, C.3
Kaestli, A.J.4
Wiggins, P.A.5
Rodrigues, L.O.6
-
130
-
-
84867878045
-
Cancer stem cell definitions and terminology: The devil is in the details
-
1:CAS:528:DC%2BC38XhsVyktbrP 23051844
-
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767-75.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 767-775
-
-
Valent, P.1
Bonnet, D.2
De Maria, R.3
Lapidot, T.4
Copland, M.5
Melo, J.V.6
-
131
-
-
84865827060
-
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia
-
4045621 22932223
-
Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra118.
-
(2012)
Sci Transl Med
, vol.4
, pp. 149ra118
-
-
Jan, M.1
Snyder, T.M.2
Corces-Zimmerman, M.R.3
Vyas, P.4
Weissman, I.L.5
Quake, S.R.6
-
132
-
-
58149296508
-
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): A proposal of the Austrian CML platform
-
1:CAS:528:DC%2BD1MXjvFOktw%3D%3D 19116712
-
Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, et al. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wien Klin Wochenschr. 2008;120:697-709.
-
(2008)
Wien Klin Wochenschr
, vol.120
, pp. 697-709
-
-
Valent, P.1
Lion, T.2
Wolf, D.3
Sillaber, C.4
Agis, H.5
Petzer, A.6
-
134
-
-
73949131456
-
Regulation of intestinal stem cells in mammals and Drosophila
-
Wang P, Hou SX. Regulation of intestinal stem cells in mammals and Drosophila. J Cell Physiol. 2009;222:33-7.
-
(2009)
J Cell Physiol
, vol.222
, pp. 33-37
-
-
Wang, P.1
Hou, S.X.2
-
136
-
-
38949105508
-
Gatekeeper function of the RUNX1 transcription factor in acute leukemia
-
1:CAS:528:DC%2BD1cXitVejsb4%3D 17920312
-
Niebuhr B, Fischer M, Tager M, Cammenga J, Stocking C. Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells Mol Dis. 2008;40:211-8.
-
(2008)
Blood Cells Mol Dis
, vol.40
, pp. 211-218
-
-
Niebuhr, B.1
Fischer, M.2
Tager, M.3
Cammenga, J.4
Stocking, C.5
-
137
-
-
84874033050
-
BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia
-
1:CAS:528:DC%2BC3sXjt1Whsb4%3D 23411734
-
Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R, et al. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood. 2013;121:1238-9.
-
(2013)
Blood
, vol.121
, pp. 1238-1239
-
-
Wang, X.1
Tripodi, J.2
Kremyanskaya, M.3
Blouin, A.4
Roda, P.5
Hoffman, R.6
-
138
-
-
84880257049
-
An evolutionary perspective on chronic myelomonocytic leukemia
-
1:CAS:528:DC%2BC3sXhtFSiu7jJ 23558522
-
Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27:1441-50.
-
(2013)
Leukemia
, vol.27
, pp. 1441-1450
-
-
Itzykson, R.1
Solary, E.2
-
139
-
-
84925019008
-
Phenotypic and functional characterization of CD34+/CD38-/CD123+ leukemic progenitor (stem) cells in AML: A flow cytometric approach
-
Herrmann H. Phenotypic and functional characterization of CD34+/CD38-/CD123+ leukemic progenitor (stem) cells in AML: a flow cytometric approach. In: 50th ASH Annual Meeting and Exposition. 2008.
-
(2008)
50th ASH Annual Meeting and Exposition
-
-
Herrmann, H.1
-
140
-
-
67649884727
-
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression
-
1:CAS:528:DC%2BD1MXntlSjtLg%3D 19385968
-
Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009;100:1062-8.
-
(2009)
Cancer Sci
, vol.100
, pp. 1062-1068
-
-
Morimoto, K.1
Kim, S.J.2
Tanei, T.3
Shimazu, K.4
Tanji, Y.5
Taguchi, T.6
-
141
-
-
54049096261
-
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
-
2602947 1:CAS:528:DC%2BD1cXht1Cms7rJ 18591932
-
Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27:6120-30.
-
(2008)
Oncogene
, vol.27
, pp. 6120-6130
-
-
Korkaya, H.1
Paulson, A.2
Iovino, F.3
Wicha, M.S.4
-
142
-
-
62749203737
-
Insulin-like growth factor 1 receptor targeted therapeutics: Novel compounds and novel treatment strategies for cancer medicine
-
1:CAS:528:DC%2BD1MXkslClt7c%3D
-
Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Patents Anticancer Drug Discov. 2009;4:54-72.
-
(2009)
Recent Patents Anticancer Drug Discov
, vol.4
, pp. 54-72
-
-
Hewish, M.1
Chau, I.2
Cunningham, D.3
-
143
-
-
59849120891
-
Control of stemness by fibroblast growth factor signaling in stem cells and cancer stem cells
-
1:CAS:528:DC%2BD1MXkvVSgt7c%3D 19149625
-
Gotoh N. Control of stemness by fibroblast growth factor signaling in stem cells and cancer stem cells. Curr Stem Cell Res Ther. 2009;4:9-15.
-
(2009)
Curr Stem Cell Res Ther
, vol.4
, pp. 9-15
-
-
Gotoh, N.1
-
144
-
-
84938971025
-
Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells
-
doi:10.1002/mc.22146
-
Koneczny I, Schulenburg A, Hudec X, Knofler M, Holzmann K, Piazza G, et al. Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. Mol Carcinog. 2014. doi:10.1002/mc.22146.
-
(2014)
Mol Carcinog
-
-
Koneczny, I.1
Schulenburg, A.2
Hudec, X.3
Knofler, M.4
Holzmann, K.5
Piazza, G.6
-
145
-
-
0033607274
-
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
-
23105 1:CAS:528:DyaK1MXnt1yqtro%3D 10536003
-
Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96:12804-9.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, pp. 12804-12809
-
-
Jiang, X.1
Lopez, A.2
Holyoake, T.3
Eaves, A.4
Eaves, C.5
-
146
-
-
0034080017
-
Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia
-
1:STN:280:DC%2BD3czit1entA%3D%3D 10865977
-
Jiang X, Fujisaki T, Nicolini F, Berger M, Holyoake T, Eisterer W, et al. Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia. Leukemia. 2000;14:1112-21.
-
(2000)
Leukemia
, vol.14
, pp. 1112-1121
-
-
Jiang, X.1
Fujisaki, T.2
Nicolini, F.3
Berger, M.4
Holyoake, T.5
Eisterer, W.6
-
147
-
-
84864780648
-
CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
-
3424958 22871210
-
Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, et al. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med. 2012;10:85.
-
(2012)
BMC Med
, vol.10
, pp. 85
-
-
Zhang, S.S.1
Han, Z.P.2
Jing, Y.Y.3
Tao, S.F.4
Li, T.J.5
Wang, H.6
-
149
-
-
77956620024
-
Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
-
1:CAS:528:DC%2BC3cXhtFOnt7%2FO 20637871
-
Tavor S, Petit I. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Semin Cancer Biol. 2010;20:178-85.
-
(2010)
Semin Cancer Biol
, vol.20
, pp. 178-185
-
-
Tavor, S.1
Petit, I.2
-
150
-
-
13744255245
-
CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice
-
1:CAS:528:DC%2BD2cXjtV2ltbw%3D 15087398
-
Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64:2817-24.
-
(2004)
Cancer Res
, vol.64
, pp. 2817-2824
-
-
Tavor, S.1
Petit, I.2
Porozov, S.3
Avigdor, A.4
Dar, A.5
Leider-Trejo, L.6
-
151
-
-
84860420791
-
Erythropoietin receptor contributes to melanoma cell survival in vivo
-
3441831 1:CAS:528:DC%2BC3MXhtVKitrvO 21860424
-
Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, et al. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene. 2012;31:1649-60.
-
(2012)
Oncogene
, vol.31
, pp. 1649-1660
-
-
Kumar, S.M.1
Zhang, G.2
Bastian, B.C.3
Arcasoy, M.O.4
Karande, P.5
Pushparajan, A.6
-
152
-
-
34547120946
-
Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis-stimulating agents in cancer patients
-
1:CAS:528:DC%2BD2sXpt1yqurY%3D 17582631
-
Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer. 2007;110:477-88.
-
(2007)
Cancer
, vol.110
, pp. 477-488
-
-
Sinclair, A.M.1
Todd, M.D.2
Forsythe, K.3
Knox, S.J.4
Elliott, S.5
Begley, C.G.6
-
154
-
-
84866332779
-
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900
-
3447784 1:CAS:528:DC%2BC38Xhtl2mu77P 22855599
-
Gonen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012;120:2297-306.
-
(2012)
Blood
, vol.120
, pp. 2297-2306
-
-
Gonen, M.1
Sun, Z.2
Figueroa, M.E.3
Patel, J.P.4
Abdel-Wahab, O.5
Racevskis, J.6
-
155
-
-
1242307379
-
Interleukin-3 receptor in acute leukemia
-
1:CAS:528:DC%2BD2cXlt1agsQ%3D%3D 14671644
-
Testa U, Riccioni R, Diverio D, Rossini A, Lo Coco F, Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18:219-26.
-
(2004)
Leukemia
, vol.18
, pp. 219-226
-
-
Testa, U.1
Riccioni, R.2
Diverio, D.3
Rossini, A.4
Lo Coco, F.5
Peschle, C.6
-
156
-
-
0042967809
-
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
-
12930926
-
Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349:743-52.
-
(2003)
N Engl J Med
, vol.349
, pp. 743-752
-
-
Lowenberg, B.1
Van Putten, W.2
Theobald, M.3
Gmur, J.4
Verdonck, L.5
Sonneveld, P.6
-
157
-
-
0037114829
-
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm
-
1:CAS:528:DC%2BD38XpsFCqsL4%3D 12393388
-
Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372-80.
-
(2002)
Blood
, vol.100
, pp. 4372-4380
-
-
Frohling, S.1
Schlenk, R.F.2
Breitruck, J.3
Benner, A.4
Kreitmeier, S.5
Tobis, K.6
-
158
-
-
0030048429
-
Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis
-
1:CAS:528:DyaK28XktF2ktL4%3D 8677752
-
Hassan HT, Zander A. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol. 1996;95:257-62.
-
(1996)
Acta Haematol
, vol.95
, pp. 257-262
-
-
Hassan, H.T.1
Zander, A.2
-
159
-
-
84860349448
-
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
-
3350358 1:CAS:528:DC%2BC38Xms1altrg%3D 22308295
-
Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119:3917-24.
-
(2012)
Blood
, vol.119
, pp. 3917-3924
-
-
Uy, G.L.1
Rettig, M.P.2
Motabi, I.H.3
McFarland, K.4
Trinkaus, K.M.5
Hladnik, L.M.6
-
160
-
-
84881256477
-
GCSF-R expression in myelodysplastic and myeloproliferative disorders and blast dysmaturation in CML
-
23897249
-
Hanumanthu VS, Pirruccello SJ. GCSF-R expression in myelodysplastic and myeloproliferative disorders and blast dysmaturation in CML. Am J Clin Pathol. 2013;140:155-64.
-
(2013)
Am J Clin Pathol
, vol.140
, pp. 155-164
-
-
Hanumanthu, V.S.1
Pirruccello, S.J.2
-
161
-
-
84871188557
-
Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome
-
1:CAS:528:DC%2BC3sXht1Wit7jI 23263827
-
Zhang Y, Guo Q, Zhao H, Zhao D, Wu X, Zhao W, et al. Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome. Med Oncol. 2013;30:341.
-
(2013)
Med Oncol
, vol.30
, pp. 341
-
-
Zhang, Y.1
Guo, Q.2
Zhao, H.3
Zhao, D.4
Wu, X.5
Zhao, W.6
-
162
-
-
0028849992
-
C-kit point mutation of extracellular domain in patients with myeloproliferative disorders
-
1:CAS:528:DyaK28XmtlQ%3D 8555071
-
Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, et al. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol. 1995;91:661-3.
-
(1995)
Br J Haematol
, vol.91
, pp. 661-663
-
-
Nakata, Y.1
Kimura, A.2
Katoh, O.3
Kawaishi, K.4
Hyodo, H.5
Abe, K.6
-
163
-
-
55049114480
-
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis
-
1:CAS:528:DC%2BD1cXhtVKmt77F 18511598
-
Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008;26:1920-30.
-
(2008)
Stem Cells
, vol.26
, pp. 1920-1930
-
-
Bogani, C.1
Ponziani, V.2
Guglielmelli, P.3
Desterke, C.4
Rosti, V.5
Bosi, A.6
-
164
-
-
75149121612
-
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
-
2804932 1:CAS:528:DC%2BC3cXot1Sk 20048335
-
Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16:338-47.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 338-347
-
-
Smith, B.D.1
Kasamon, Y.L.2
Kowalski, J.3
Gocke, C.4
Murphy, K.5
Miller, C.B.6
-
165
-
-
84884752554
-
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors
-
3894913 1:CAS:528:DC%2BC3sXhsVCqs7fL 23887971
-
Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, et al. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res. 2013;73:5775-86.
-
(2013)
Cancer Res
, vol.73
, pp. 5775-5786
-
-
Corbin, A.S.1
O'Hare, T.2
Gu, Z.3
Kraft, I.L.4
Eiring, A.M.5
Khorashad, J.S.6
-
166
-
-
84899794191
-
Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo
-
1:CAS:528:DC%2BC2cXnsFWjsbk%3D 24502926
-
Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, et al. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther. 2014;13:1155-69.
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 1155-1169
-
-
Beider, K.1
Darash-Yahana, M.2
Blaier, O.3
Koren-Michowitz, M.4
Abraham, M.5
Wald, H.6
-
167
-
-
84911880240
-
Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia
-
4203245 25337274
-
Gaikwad AS, Donohue RE, Elghetany MT, Sheehan AM, Lu XY, Gramatges MM, et al. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2014;7:6225-30.
-
(2014)
Int J Clin Exp Pathol
, vol.7
, pp. 6225-6230
-
-
Gaikwad, A.S.1
Donohue, R.E.2
Elghetany, M.T.3
Sheehan, A.M.4
Lu, X.Y.5
Gramatges, M.M.6
-
168
-
-
77953612149
-
A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia
-
1:CAS:528:DC%2BC3cXnsVartLw%3D 20137810
-
Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk Res. 2010;34:1035-42.
-
(2010)
Leuk Res
, vol.34
, pp. 1035-1042
-
-
Kim, H.P.1
Frankel, A.E.2
Hogge, D.E.3
-
169
-
-
80051787355
-
Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
-
3135709 1:CAS:528:DC%2BC3MXpvFWksro%3D 21483439
-
Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 2011;25:1314-23.
-
(2011)
Leukemia
, vol.25
, pp. 1314-1323
-
-
Parameswaran, R.1
Yu, M.2
Lim, M.3
Groffen, J.4
Heisterkamp, N.5
-
170
-
-
84892747374
-
The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma
-
1:CAS:528:DC%2BC2cXhtFKrsL4%3D 24246358
-
Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2014;20:469-79.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 469-479
-
-
Peled, A.1
Abraham, M.2
Avivi, I.3
Rowe, J.M.4
Beider, K.5
Wald, H.6
-
171
-
-
0036643778
-
Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF
-
1:CAS:528:DC%2BD38XksVGntL0%3D 12115579
-
LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer. 2002;100:2-8.
-
(2002)
Int J Cancer
, vol.100
, pp. 2-8
-
-
Lebedis, C.1
Chen, K.2
Fallavollita, L.3
Boutros, T.4
Brodt, P.5
-
172
-
-
84879092200
-
HER2 and breast cancer stem cells: More than meets the eye
-
1:CAS:528:DC%2BC3sXpsVensr8%3D 23740771
-
Korkaya H, Wicha MS. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res. 2013;73:3489-93.
-
(2013)
Cancer Res
, vol.73
, pp. 3489-3493
-
-
Korkaya, H.1
Wicha, M.S.2
-
173
-
-
78650732630
-
Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling
-
3003123 1:CAS:528:DC%2BC3cXhs1WjsrnI 21098263
-
Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A. 2010;107:21737-42.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 21737-21742
-
-
Fillmore, C.M.1
Gupta, P.B.2
Rudnick, J.A.3
Caballero, S.4
Keller, P.J.5
Lander, E.S.6
-
174
-
-
0028075837
-
Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells
-
1:CAS:528:DyaK2cXmt1Omtbo%3D 7929366
-
Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem. 1994;269:26449-55.
-
(1994)
J Biol Chem
, vol.269
, pp. 26449-26455
-
-
Sun, L.1
Wu, G.2
Willson, J.K.3
Zborowska, E.4
Yang, J.5
Rajkarunanayake, I.6
-
175
-
-
33847663871
-
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
-
1:STN:280:DC%2BD2s7hsVKjsA%3D%3D 17164226
-
Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18:510-7.
-
(2007)
Ann Oncol
, vol.18
, pp. 510-517
-
-
Pinto, C.1
Di Fabio, F.2
Siena, S.3
Cascinu, S.4
Rojas Llimpe, F.L.5
Ceccarelli, C.6
-
176
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
-
1:CAS:528:DC%2BC3cXhtVymt7zO 20728210
-
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.J.1
Van Cutsem, E.2
Feyereislova, A.3
Chung, H.C.4
Shen, L.5
Sawaki, A.6
-
177
-
-
84995743878
-
Markers of resistance to anti-EGFR therapy in colorectal cancer
-
3712296 1:CAS:528:DC%2BC2cXht1Sku7jJ 23997942
-
Shaib W, Mahajan R, El-Rayes B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol. 2013;4:308-18.
-
(2013)
J Gastrointest Oncol
, vol.4
, pp. 308-318
-
-
Shaib, W.1
Mahajan, R.2
El-Rayes, B.3
-
178
-
-
18444401114
-
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival
-
1:CAS:528:DC%2BD2MXktleqtrg%3D 15837989
-
Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744-53.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2744-2753
-
-
Kim, J.1
Takeuchi, H.2
Lam, S.T.3
Turner, R.R.4
Wang, H.J.5
Kuo, C.6
-
179
-
-
58249092146
-
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
-
2645084 19064975
-
Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009;27:176-85.
-
(2009)
J Clin Oncol
, vol.27
, pp. 176-185
-
-
Wolpin, B.M.1
Meyerhardt, J.A.2
Chan, A.T.3
Ng, K.4
Chan, J.A.5
Wu, K.6
-
180
-
-
84869021181
-
Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation
-
3512565 1:CAS:528:DC%2BC38Xhs1KlsbrP 23153532
-
Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571-84.
-
(2012)
Cancer Cell
, vol.22
, pp. 571-584
-
-
Calon, A.1
Espinet, E.2
Palomo-Ponce, S.3
Tauriello, D.V.4
Iglesias, M.5
Cespedes, M.V.6
-
181
-
-
33646864481
-
EGFR mutation in gefitinib-responsive small-cell lung cancer
-
1:STN:280:DC%2BD283nslegsQ%3D%3D 16357019
-
Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol. 2006;17:1028-9.
-
(2006)
Ann Oncol
, vol.17
, pp. 1028-1029
-
-
Okamoto, I.1
Araki, J.2
Suto, R.3
Shimada, M.4
Nakagawa, K.5
Fukuoka, M.6
-
182
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
1:CAS:528:DC%2BD2sXmvVWmsr0%3D 17452677
-
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
Figer, A.4
Hecht, J.R.5
Gallinger, S.6
-
183
-
-
84865555780
-
Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma
-
1:CAS:528:DC%2BC38Xht1Kit7nL 22473773
-
Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004-14.
-
(2012)
Hepatology
, vol.56
, pp. 1004-1014
-
-
Shan, J.1
Shen, J.2
Liu, L.3
Xia, F.4
Xu, C.5
Duan, G.6
-
184
-
-
0021932240
-
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
-
1:CAS:528:DyaL2MXhtVOgsbg%3D 2981413
-
Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985;313:144-7.
-
(1985)
Nature
, vol.313
, pp. 144-147
-
-
Libermann, T.A.1
Nusbaum, H.R.2
Razon, N.3
Kris, R.4
Lax, I.5
Soreq, H.6
-
185
-
-
0026772431
-
Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops
-
1:CAS:528:DyaK38Xkt1Cjsbw%3D 1317261
-
Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992;52:3213-9.
-
(1992)
Cancer Res
, vol.52
, pp. 3213-3219
-
-
Hermanson, M.1
Funa, K.2
Hartman, M.3
Claesson-Welsh, L.4
Heldin, C.H.5
Westermark, B.6
-
186
-
-
58149314184
-
CXCR4 mediates the proliferation of glioblastoma progenitor cells
-
2628453 1:CAS:528:DC%2BD1MXns12qtw%3D%3D 19008040
-
Ehtesham M, Mapara KY, Stevenson CB, Thompson RC. CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett. 2009;274:305-12.
-
(2009)
Cancer Lett
, vol.274
, pp. 305-312
-
-
Ehtesham, M.1
Mapara, K.Y.2
Stevenson, C.B.3
Thompson, R.C.4
-
187
-
-
63249123273
-
TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma
-
1:CAS:528:DC%2BD1MXlsFyrtLo%3D 19345330
-
Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15:315-27.
-
(2009)
Cancer Cell
, vol.15
, pp. 315-327
-
-
Penuelas, S.1
Anido, J.2
Prieto-Sanchez, R.M.3
Folch, G.4
Barba, I.5
Cuartas, I.6
-
188
-
-
84864863728
-
MET signaling regulates glioblastoma stem cells
-
1:CAS:528:DC%2BC38XhtFant7rO 22617325
-
Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, et al. MET signaling regulates glioblastoma stem cells. Cancer Res. 2012;72:3828-38.
-
(2012)
Cancer Res
, vol.72
, pp. 3828-3838
-
-
Joo, K.M.1
Jin, J.2
Kim, E.3
Ho Kim, K.4
Kim, Y.5
Gu Kang, B.6
-
189
-
-
84885182699
-
Targeting EGFR and PI3K pathways in ovarian cancer
-
3790180 1:CAS:528:DC%2BC3sXhsVCqur3K 24022196
-
Glaysher S, Bolton LM, Johnson P, Atkey N, Dyson M, Torrance C, et al. Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer. 2013;109:1786-94.
-
(2013)
Br J Cancer
, vol.109
, pp. 1786-1794
-
-
Glaysher, S.1
Bolton, L.M.2
Johnson, P.3
Atkey, N.4
Dyson, M.5
Torrance, C.6
-
190
-
-
0037440042
-
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
-
1:CAS:528:DC%2BD2cXpsVWqs70%3D 12525520
-
Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:283-90.
-
(2003)
J Clin Oncol
, vol.21
, pp. 283-290
-
-
Bookman, M.A.1
Darcy, K.M.2
Clarke-Pearson, D.3
Boothby, R.A.4
Horowitz, I.R.5
-
191
-
-
84882661249
-
TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment
-
3745588 1:CAS:528:DC%2BC3sXht1OisrbE 23824740
-
Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013;73:5016-28.
-
(2013)
Cancer Res
, vol.73
, pp. 5016-5028
-
-
Yeung, T.L.1
Leung, C.S.2
Wong, K.K.3
Samimi, G.4
Thompson, M.S.5
Liu, J.6
-
192
-
-
84863180510
-
CXCR4 expression in prostate cancer progenitor cells
-
3281066 1:CAS:528:DC%2BC38XjtVektbY%3D 22359577
-
Dubrovska A, Elliott J, Salamone RJ, Telegeev GD, Stakhovsky AE, Schepotin IB, et al. CXCR4 expression in prostate cancer progenitor cells. PLoS One. 2012;7:e31226.
-
(2012)
PLoS One
, vol.7
, pp. 31226
-
-
Dubrovska, A.1
Elliott, J.2
Salamone, R.J.3
Telegeev, G.D.4
Stakhovsky, A.E.5
Schepotin, I.B.6
-
193
-
-
67349108316
-
CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion
-
2696769 1:CAS:528:DC%2BD1MXlslCht7g%3D 19401689
-
Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer. 2009;100:1638-46.
-
(2009)
Br J Cancer
, vol.100
, pp. 1638-1646
-
-
Singh, S.1
Nannuru, K.C.2
Sadanandam, A.3
Varney, M.L.4
Singh, R.K.5
-
194
-
-
84896735337
-
Developmental signaling pathways in cancer stem cells of solid tumors
-
Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta. 1830;2013:2481-95.
-
(1830)
Biochim Biophys Acta
, vol.2013
, pp. 2481-2495
-
-
Karamboulas, C.1
Ailles, L.2
-
195
-
-
79956152511
-
Effects of combination of Notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells
-
1:CAS:528:DC%2BC3MXmslymtrc%3D 21498710
-
Okuhashi Y, Itoh M, Nara N, Tohda S. Effects of combination of Notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells. Anticancer Res. 2011;31:893-6.
-
(2011)
Anticancer Res
, vol.31
, pp. 893-896
-
-
Okuhashi, Y.1
Itoh, M.2
Nara, N.3
Tohda, S.4
-
196
-
-
84881360762
-
Targeting survival pathways in chronic myeloid leukaemia stem cells
-
3753830 1:CAS:528:DC%2BC3sXht1elsrbM 23517124
-
Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol. 2013;169:1693-707.
-
(2013)
Br J Pharmacol
, vol.169
, pp. 1693-1707
-
-
Sinclair, A.1
Latif, A.L.2
Holyoake, T.L.3
-
197
-
-
84930899800
-
Biomarkers and signaling pathways of colorectal cancer stem cells
-
doi:10.1007/s13277-015-3198-4
-
Abetov D, Mustapova Z, Saliev T, Bulanin D. Biomarkers and signaling pathways of colorectal cancer stem cells. Tumour Biol. 2015;doi:10.1007/s13277-015-3198-4.
-
(2015)
Tumour Biol
-
-
Abetov, D.1
Mustapova, Z.2
Saliev, T.3
Bulanin, D.4
-
198
-
-
77953715690
-
Targeting Wnt signaling: Can we safely eradicate cancer stem cells?
-
1:CAS:528:DC%2BC3cXntlKru7o%3D 20530697
-
Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16:3153-62.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3153-3162
-
-
Takahashi-Yanaga, F.1
Kahn, M.2
-
199
-
-
84866467141
-
Loss of the tumor suppressor BAP1 causes myeloid transformation
-
1:CAS:528:DC%2BC38XhtlGrtbfF 22878500
-
Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012;337:1541-6.
-
(2012)
Science
, vol.337
, pp. 1541-1546
-
-
Dey, A.1
Seshasayee, D.2
Noubade, R.3
French, D.M.4
Liu, J.5
Chaurushiya, M.S.6
-
200
-
-
84859552482
-
Targeting beta-catenin in CML: Leukemia stem cells beware!
-
1:CAS:528:DC%2BC38XlsFGiu7w%3D 22482499
-
Kleppe M, Levine RL. Targeting beta-catenin in CML: leukemia stem cells beware! Cell Stem Cell. 2012;10:351-3.
-
(2012)
Cell Stem Cell
, vol.10
, pp. 351-353
-
-
Kleppe, M.1
Levine, R.L.2
-
201
-
-
77953700950
-
Targeting Notch to target cancer stem cells
-
3008160 1:CAS:528:DC%2BC3cXntlKru70%3D 20530696
-
Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010;16:3141-52.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3141-3152
-
-
Pannuti, A.1
Foreman, K.2
Rizzo, P.3
Osipo, C.4
Golde, T.5
Osborne, B.6
-
202
-
-
77953693899
-
Targeting hedgehog - A cancer stem cell pathway
-
2888641 1:CAS:528:DC%2BC3cXntlKru7w%3D 20530699
-
Merchant AA, Matsui W. Targeting hedgehog - a cancer stem cell pathway. Clin Cancer Res. 2010;16:3130-40.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3130-3140
-
-
Merchant, A.A.1
Matsui, W.2
-
203
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
-
1:CAS:528:DyaK28Xislyhs70%3D 8616716
-
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-6.
-
(1996)
Nat Med
, vol.2
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchdunger, E.3
Ohno, S.4
Segal, G.M.5
Fanning, S.6
-
204
-
-
78650949272
-
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
-
3007128 1:CAS:528:DC%2BC3MXis1yltA%3D%3D 21157039
-
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396-409.
-
(2011)
J Clin Invest
, vol.121
, pp. 396-409
-
-
Corbin, A.S.1
Agarwal, A.2
Loriaux, M.3
Cortes, J.4
Deininger, M.W.5
Druker, B.J.6
-
205
-
-
33744491524
-
BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry
-
1:CAS:528:DC%2BD28XkvVymtLw%3D 16572205
-
Hamilton A, Elrick L, Myssina S, Copland M, Jorgensen H, Melo JV, et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia. 2006;20:1035-9.
-
(2006)
Leukemia
, vol.20
, pp. 1035-1039
-
-
Hamilton, A.1
Elrick, L.2
Myssina, S.3
Copland, M.4
Jorgensen, H.5
Melo, J.V.6
-
206
-
-
84902529277
-
The variety of leukemic stem cells in myeloid malignancy
-
23831573
-
Wiseman DH, Greystoke BF, Somervaille TC. The variety of leukemic stem cells in myeloid malignancy. Oncogene. 2013;33(24):3091-8.
-
(2013)
Oncogene
, vol.33
, Issue.24
, pp. 3091-3098
-
-
Wiseman, D.H.1
Greystoke, B.F.2
Somervaille, T.C.3
-
207
-
-
78751644099
-
Genetic variegation of clonal architecture and propagating cells in leukaemia
-
1:CAS:528:DC%2BC3cXhsFKmu7jJ 21160474
-
Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469:356-61.
-
(2011)
Nature
, vol.469
, pp. 356-361
-
-
Anderson, K.1
Lutz, C.2
Van Delft, F.W.3
Bateman, C.M.4
Guo, Y.5
Colman, S.M.6
-
208
-
-
33745187852
-
Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis
-
1:CAS:528:DC%2BD28XlvFGjtbg%3D 16688229
-
Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006;20:1211-6.
-
(2006)
Leukemia
, vol.20
, pp. 1211-1216
-
-
Ysebaert, L.1
Chicanne, G.2
Demur, C.3
De Toni, F.4
Prade-Houdellier, N.5
Ruidavets, J.B.6
-
209
-
-
9144269759
-
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells
-
307657 1:CAS:528:DC%2BD2cXhtVCltA%3D%3D 14668450
-
Li Y, Welm B, Podsypanina K, Huang SX, Chamorro M, Zhang XM, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A. 2003;100:15853-8.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 15853-15858
-
-
Li, Y.1
Welm, B.2
Podsypanina, K.3
Huang, S.X.4
Chamorro, M.5
Zhang, X.M.6
-
210
-
-
59049101982
-
Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model
-
2626610 1:CAS:528:DC%2BD1MXhsFyisr0%3D 19144919
-
Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A. 2009;106:1193-8.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 1193-1198
-
-
Chien, A.J.1
Moore, E.C.2
Lonsdorf, A.S.3
Kulikauskas, R.M.4
Rothberg, B.G.5
Berger, A.J.6
-
211
-
-
49249122615
-
Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells
-
1:CAS:528:DC%2BD1cXmsFKmur8%3D 18519688
-
Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68:4287-95.
-
(2008)
Cancer Res
, vol.68
, pp. 4287-4295
-
-
Yang, W.1
Yan, H.X.2
Chen, L.3
Liu, Q.4
He, Y.Q.5
Yu, L.X.6
-
212
-
-
84861111256
-
The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: The role of the endothelial network
-
22251985
-
Gursel DB, Berry N, Boockvar JA. The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: the role of the endothelial network. Neurosurgery. 2012;70:N19-21.
-
(2012)
Neurosurgery
, vol.70
, pp. 19-21
-
-
Gursel, D.B.1
Berry, N.2
Boockvar, J.A.3
-
213
-
-
76749112922
-
NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer
-
4010106 1:CAS:528:DC%2BC3cXhvFaksLs%3D 20145124
-
Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010;70:1469-78.
-
(2010)
Cancer Res
, vol.70
, pp. 1469-1478
-
-
Sikandar, S.S.1
Pate, K.T.2
Anderson, S.3
Dizon, D.4
Edwards, R.A.5
Waterman, M.L.6
-
214
-
-
63849329353
-
A functional Notch-survivin gene signature in basal breast cancer
-
2656893 19025652
-
Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res. 2008;10:R97.
-
(2008)
Breast Cancer Res
, vol.10
, pp. 97
-
-
Lee, C.W.1
Simin, K.2
Liu, Q.3
Plescia, J.4
Guha, M.5
Khan, A.6
-
215
-
-
33745728170
-
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells
-
1:CAS:528:DC%2BD28XlvVSksrY%3D 16778178
-
Liu SL, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66:6063-71.
-
(2006)
Cancer Res
, vol.66
, pp. 6063-6071
-
-
Liu, S.L.1
Dontu, G.2
Mantle, I.D.3
Patel, S.4
Ahn, N.S.5
Jackson, K.W.6
-
216
-
-
84924975985
-
Inhibition of Hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance
-
Huang FT, Zhuan-Sun YX, Zhuang YY, Wei SL, Tang J, Chen WB, et al. Inhibition of Hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. J Gastroen Hepatol. 2012;27:43.
-
(2012)
J Gastroen Hepatol
, vol.27
, pp. 43
-
-
Huang, F.T.1
Zhuan-Sun, Y.X.2
Zhuang, Y.Y.3
Wei, S.L.4
Tang, J.5
Chen, W.B.6
-
217
-
-
79956141118
-
Promotion of the self-renewal capacity of human leukemia cells by sonic hedgehog protein
-
1:CAS:528:DC%2BC3MXmslymsbk%3D 21498696
-
Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Murohashi I, Nara N, Tohda S. Promotion of the self-renewal capacity of human leukemia cells by sonic hedgehog protein. Anticancer Res. 2011;31:781-4.
-
(2011)
Anticancer Res
, vol.31
, pp. 781-784
-
-
Kawaguchi-Ihara, N.1
Okuhashi, Y.2
Itoh, M.3
Murohashi, I.4
Nara, N.5
Tohda, S.6
-
218
-
-
84861614106
-
In vitro and in vivo characterization of a novel hedgehog signaling antagonist in human glioblastoma cell lines
-
1:CAS:528:DC%2BC38XhsVCitLs%3D 22072503
-
Ferruzzi P, Mennillo F, De Rosa A, Giordano C, Rossi M, Benedetti G, et al. In vitro and in vivo characterization of a novel hedgehog signaling antagonist in human glioblastoma cell lines. Int J Cancer. 2012;131:E33-44.
-
(2012)
Int J Cancer
, vol.131
, pp. 33-44
-
-
Ferruzzi, P.1
Mennillo, F.2
De Rosa, A.3
Giordano, C.4
Rossi, M.5
Benedetti, G.6
-
219
-
-
79551540949
-
Hedgehog signaling drives cellular survival in human colon carcinoma cells
-
3032813 1:CAS:528:DC%2BC3MXhsVCisro%3D 21135115
-
Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res. 2011;71:1092-102.
-
(2011)
Cancer Res
, vol.71
, pp. 1092-1102
-
-
Mazumdar, T.1
Devecchio, J.2
Shi, T.3
Jones, J.4
Agyeman, A.5
Houghton, J.A.6
-
220
-
-
65549159598
-
A two-step model for colon adenoma initiation and progression caused by APC loss
-
2706149 1:CAS:528:DC%2BD1MXosVCltrg%3D 19450512
-
Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell. 2009;137:623-34.
-
(2009)
Cell
, vol.137
, pp. 623-634
-
-
Phelps, R.A.1
Chidester, S.2
Dehghanizadeh, S.3
Phelps, J.4
Sandoval, I.T.5
Rai, K.6
-
221
-
-
67649969473
-
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling
-
2683567 19492080
-
Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7:e1000121.
-
(2009)
PLoS Biol
, vol.7
, pp. 1000121
-
-
Korkaya, H.1
Paulson, A.2
Charafe-Jauffret, E.3
Ginestier, C.4
Brown, M.5
Dutcher, J.6
-
222
-
-
84882714320
-
JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells
-
1:CAS:528:DC%2BC3sXht1Ois7%2FP 23824741
-
Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 2013;73:5288-98.
-
(2013)
Cancer Res
, vol.73
, pp. 5288-5298
-
-
Kroon, P.1
Berry, P.A.2
Stower, M.J.3
Rodrigues, G.4
Mann, V.M.5
Simms, M.6
-
223
-
-
84873625209
-
The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway
-
1:CAS:528:DC%2BC3sXkt1Kiu78%3D 23338840
-
Kanno H, Sato H, Yokoyama T-A, Yoshizumi T, Yamada S. The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway. Int J Oncol. 2013;42:881-6.
-
(2013)
Int J Oncol
, vol.42
, pp. 881-886
-
-
Kanno, H.1
Sato, H.2
Yokoyama, T.-A.3
Yoshizumi, T.4
Yamada, S.5
-
224
-
-
33749521890
-
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells
-
1:CAS:528:DC%2BD28XhtVChsrjK 16998483
-
Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12:1175-80.
-
(2006)
Nat Med
, vol.12
, pp. 1175-1180
-
-
Krause, D.S.1
Lazarides, K.2
Von Andrian, U.H.3
Van Etten, R.A.4
-
225
-
-
77954219134
-
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
-
3285111 1:CAS:528:DC%2BC3cXosV2is70%3D 20382130
-
Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol. 2010;80:602-12.
-
(2010)
Biochem Pharmacol
, vol.80
, pp. 602-612
-
-
Nair, R.R.1
Tolentino, J.2
Hazlehurst, L.A.3
-
226
-
-
0025641727
-
Stem cells: Attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt
-
1:STN:280:DyaK3MzgtFShug%3D%3D 2100251
-
Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development. 1990;110:1001-20.
-
(1990)
Development
, vol.110
, pp. 1001-1020
-
-
Potten, C.S.1
Loeffler, M.2
-
227
-
-
37549069749
-
No place like home: Anatomy and function of the stem cell niche
-
1:CAS:528:DC%2BD2sXhsVKrsr3J 18097443
-
Jones DL, Wagers AJ. No place like home: anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol. 2008;9:11-21.
-
(2008)
Nat Rev Mol Cell Biol
, vol.9
, pp. 11-21
-
-
Jones, D.L.1
Wagers, A.J.2
-
228
-
-
0345004813
-
Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation
-
1:CAS:528:DyaK1MXivVyhtr4%3D 10210328
-
Rosel M, Khaldoyanidi S, Zawadzki V, Zoller M. Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol. 1999;27:698-711.
-
(1999)
Exp Hematol
, vol.27
, pp. 698-711
-
-
Rosel, M.1
Khaldoyanidi, S.2
Zawadzki, V.3
Zoller, M.4
-
229
-
-
62149144443
-
Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133(+) hematopoietic stem cells during ex vivo expansion
-
1:CAS:528:DC%2BD1MXjsVOhtr0%3D 19216019
-
Alakel N, Jing D, Muller K, Bornhauser M, Ehninger G, Ordemann R. Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133(+) hematopoietic stem cells during ex vivo expansion. Exp Hematol. 2009;37(4):504-13.
-
(2009)
Exp Hematol
, vol.37
, Issue.4
, pp. 504-513
-
-
Alakel, N.1
Jing, D.2
Muller, K.3
Bornhauser, M.4
Ehninger, G.5
Ordemann, R.6
-
230
-
-
67650002410
-
L1 cell adhesion molecule (L1CAM) in invasive tumors
-
1:CAS:528:DC%2BD1MXosVajurk%3D 19144458
-
Raveh S, Gavert N, Ben-Ze'ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 2009;282(2):137-45.
-
(2009)
Cancer Lett
, vol.282
, Issue.2
, pp. 137-145
-
-
Raveh, S.1
Gavert, N.2
Ben-Ze'Ev, A.3
-
232
-
-
51049101689
-
Targeting cancer stem cells through L1CAM suppresses glioma growth
-
2739001 1:CAS:528:DC%2BD1cXpt1Sqt7w%3D 18676824
-
Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008;68:6043-8.
-
(2008)
Cancer Res
, vol.68
, pp. 6043-6048
-
-
Bao, S.1
Wu, Q.2
Li, Z.3
Sathornsumetee, S.4
Wang, H.5
McLendon, R.E.6
-
233
-
-
4043052971
-
Epithelial-mesenchymal transitions: Twist in development and metastasis
-
1:CAS:528:DC%2BD2cXmslKrs7w%3D 15294153
-
Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277-9.
-
(2004)
Cell
, vol.118
, pp. 277-279
-
-
Kang, Y.1
Massague, J.2
-
234
-
-
18344389548
-
Immature leukemic CD34(+)CXCR4(+) cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1
-
1:CAS:528:DC%2BD38Xktlylu7g%3D 12004084
-
Peled A, Hardan I, Trakhtenbrot L, Gur E, Magid M, Darash-Yahana M, et al. Immature leukemic CD34(+)CXCR4(+) cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells. 2002;20:259-66.
-
(2002)
Stem Cells
, vol.20
, pp. 259-266
-
-
Peled, A.1
Hardan, I.2
Trakhtenbrot, L.3
Gur, E.4
Magid, M.5
Darash-Yahana, M.6
-
235
-
-
84859832491
-
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia
-
3332001 1:CAS:528:DC%2BC38XlvVSnur4%3D 22516264
-
Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21:577-92.
-
(2012)
Cancer Cell
, vol.21
, pp. 577-592
-
-
Zhang, B.1
Ho, Y.W.2
Huang, Q.3
Maeda, T.4
Lin, A.5
Lee, S.U.6
-
236
-
-
33745635043
-
The stem-cell niche as an entity of action
-
1:CAS:528:DC%2BD28XmtlahsrY%3D 16810242
-
Scadden DT. The stem-cell niche as an entity of action. Nature. 2006;441:1075-9.
-
(2006)
Nature
, vol.441
, pp. 1075-1079
-
-
Scadden, D.T.1
-
237
-
-
0025768012
-
The hematopoietic microenvironment
-
1:STN:280:DyaK3MzlsVGhtA%3D%3D 1883527
-
Greenberger JS. The hematopoietic microenvironment. Crit Rev Oncol Hematol. 1991;11:65-84.
-
(1991)
Crit Rev Oncol Hematol
, vol.11
, pp. 65-84
-
-
Greenberger, J.S.1
-
238
-
-
0023813392
-
Cellular interactions
-
1:CAS:528:DyaL1cXls1Oksro%3D 3042038
-
Torok-Storb B. Cellular interactions. Blood. 1988;72:373-85.
-
(1988)
Blood
, vol.72
, pp. 373-385
-
-
Torok-Storb, B.1
-
240
-
-
0027982876
-
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
-
1:CAS:528:DyaK2cXhs1Srtrg%3D 7507411
-
Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-14.
-
(1994)
Cell
, vol.76
, pp. 301-314
-
-
Springer, T.A.1
-
241
-
-
0038481970
-
The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited
-
1:CAS:528:DC%2BD3sXktFOnsbg%3D 12778135
-
Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-8.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 453-458
-
-
Fidler, I.J.1
-
242
-
-
0029947679
-
Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18
-
1:CAS:528:DyaK28XjvFSnsbY%3D 8704169
-
Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 1996;88:146-57.
-
(1996)
Blood
, vol.88
, pp. 146-157
-
-
Diacovo, T.G.1
Roth, S.J.2
Buccola, J.M.3
Bainton, D.F.4
Springer, T.A.5
-
243
-
-
35349026780
-
CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2)
-
1:CAS:528:DC%2BD2sXhtlWjsL3F 17708598
-
Schulenburg A, Cech P, Herbacek I, Marian B, Wrba F, Valent P, et al. CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol. 2007;213:152-60.
-
(2007)
J Pathol
, vol.213
, pp. 152-160
-
-
Schulenburg, A.1
Cech, P.2
Herbacek, I.3
Marian, B.4
Wrba, F.5
Valent, P.6
-
244
-
-
84873050284
-
Regulatory networks defining EMT during cancer initiation and progression
-
23344542
-
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97-110.
-
(2013)
Nat Rev Cancer
, vol.13
, pp. 97-110
-
-
De Craene, B.1
Berx, G.2
-
245
-
-
78649369742
-
The epithelial-mesenchymal transition (EMT) phenomenon
-
20943648
-
Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21 Suppl 7:vii89-92.
-
(2010)
Ann Oncol
, vol.21
, Issue.7
, pp. 89-92
-
-
Savagner, P.1
-
246
-
-
0033824642
-
Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells
-
1:CAS:528:DC%2BD3cXntFOhtrk%3D 10995013
-
Durig J, Rosenthal C, Elmaagacli A, Heyworth C, Halfmeyer K, Kasper C, et al. Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells. Leukemia. 2000;14:1652-60.
-
(2000)
Leukemia
, vol.14
, pp. 1652-1660
-
-
Durig, J.1
Rosenthal, C.2
Elmaagacli, A.3
Heyworth, C.4
Halfmeyer, K.5
Kasper, C.6
-
247
-
-
84886947010
-
Arteriolar niches maintain haematopoietic stem cell quiescence
-
1:CAS:528:DC%2BC3sXhs12lt7fN 24107994
-
Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 2013;502:637-43.
-
(2013)
Nature
, vol.502
, pp. 637-643
-
-
Kunisaki, Y.1
Bruns, I.2
Scheiermann, C.3
Ahmed, J.4
Pinho, S.5
Zhang, D.6
-
248
-
-
84897132895
-
Nice neighborhood: Emerging concepts of the stem cell niche
-
1:CAS:528:DC%2BC2cXmtVCqsL4%3D 24679525
-
Scadden DT. Nice neighborhood: emerging concepts of the stem cell niche. Cell. 2014;157:41-50.
-
(2014)
Cell
, vol.157
, pp. 41-50
-
-
Scadden, D.T.1
-
249
-
-
84892610064
-
The bone marrow niche for haematopoietic stem cells
-
1:CAS:528:DC%2BC2cXotFGjsg%3D%3D 24429631
-
Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327-34.
-
(2014)
Nature
, vol.505
, pp. 327-334
-
-
Morrison, S.J.1
Scadden, D.T.2
-
250
-
-
70349735988
-
Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches
-
3640296 1:CAS:528:DC%2BD1MXht1OgtbrF 19632887
-
Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009;12:103-13.
-
(2009)
Drug Resist Updat
, vol.12
, pp. 103-113
-
-
Konopleva, M.1
Tabe, Y.2
Zeng, Z.3
Andreeff, M.4
-
251
-
-
84922135666
-
The metabolic milieu of metastases
-
1:CAS:528:DC%2BC2MXitFylsLc%3D 25635452
-
Sullivan WJ, Christofk HR. The metabolic milieu of metastases. Cell. 2015;160:363-4.
-
(2015)
Cell
, vol.160
, pp. 363-364
-
-
Sullivan, W.J.1
Christofk, H.R.2
-
252
-
-
84921374070
-
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype
-
25587023
-
Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, et al. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget. 2014;5:12509-27.
-
(2014)
Oncotarget
, vol.5
, pp. 12509-12527
-
-
Xiang, L.1
Gilkes, D.M.2
Hu, H.3
Takano, N.4
Luo, W.5
Lu, H.6
-
253
-
-
69249118662
-
Low oxygen enhances primitive and definitive neural stem cell colony formation by inhibiting distinct cell death pathways
-
2771103 1:CAS:528:DC%2BD1MXht1ajsrzM 19544448
-
Clarke L, van der Kooy D. Low oxygen enhances primitive and definitive neural stem cell colony formation by inhibiting distinct cell death pathways. Stem Cells. 2009;27:1879-86.
-
(2009)
Stem Cells
, vol.27
, pp. 1879-1886
-
-
Clarke, L.1
Van Der Kooy, D.2
-
254
-
-
74049123519
-
FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status
-
2801260 1:CAS:528:DC%2BC3cXkvFar 19897487
-
Moreno-Manzano V, Rodriguez-Jimenez FJ, Acena-Bonilla JL, Fustero-Lardies S, Erceg S, Dopazo J, et al. FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem. 2010;285:1333-42.
-
(2010)
J Biol Chem
, vol.285
, pp. 1333-1342
-
-
Moreno-Manzano, V.1
Rodriguez-Jimenez, F.J.2
Acena-Bonilla, J.L.3
Fustero-Lardies, S.4
Erceg, S.5
Dopazo, J.6
-
255
-
-
34547873919
-
Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow
-
1:CAS:528:DC%2BD2sXhtVSqsbbJ 17478585
-
Levesque JP, Winkler IG, Hendy J, Williams B, Helwani F, Barbier V, et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells. 2007;25:1954-65.
-
(2007)
Stem Cells
, vol.25
, pp. 1954-1965
-
-
Levesque, J.P.1
Winkler, I.G.2
Hendy, J.3
Williams, B.4
Helwani, F.5
Barbier, V.6
-
256
-
-
4043184065
-
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
-
1:CAS:528:DC%2BD2cXmtFWrtr0%3D 15235597
-
Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858-64.
-
(2004)
Nat Med
, vol.10
, pp. 858-864
-
-
Ceradini, D.J.1
Kulkarni, A.R.2
Callaghan, M.J.3
Tepper, O.M.4
Bastidas, N.5
Kleinman, M.E.6
-
257
-
-
27644561755
-
Hypoxia requires notch signaling to maintain the undifferentiated cell state
-
1:CAS:528:DC%2BD2MXht1alsLrL 16256737
-
Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005;9:617-28.
-
(2005)
Dev Cell
, vol.9
, pp. 617-628
-
-
Gustafsson, M.V.1
Zheng, X.2
Pereira, T.3
Gradin, K.4
Jin, S.5
Lundkvist, J.6
-
258
-
-
34548599785
-
Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung
-
1:CAS:528:DC%2BD2sXpvFKjtrs%3D 17804701
-
Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007;67:7954-9.
-
(2007)
Cancer Res
, vol.67
, pp. 7954-7959
-
-
Chen, Y.1
De Marco, M.A.2
Graziani, I.3
Gazdar, A.F.4
Strack, P.R.5
Miele, L.6
-
259
-
-
34648821254
-
Making a tumour's bed: Glioblastoma stem cells and the vascular niche
-
1:CAS:528:DC%2BD2sXhtVOnsrzM 17882276
-
Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733-6.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 733-736
-
-
Gilbertson, R.J.1
Rich, J.N.2
-
260
-
-
84860819704
-
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors
-
3359741 1:CAS:528:DC%2BC38XmvV2rt74%3D 22411871
-
Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 2012;119:4253-63.
-
(2012)
Blood
, vol.119
, pp. 4253-4263
-
-
Nieborowska-Skorska, M.1
Kopinski, P.K.2
Ray, R.3
Hoser, G.4
Ngaba, D.5
Flis, S.6
-
261
-
-
84888412157
-
ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells
-
3858895 1:CAS:528:DC%2BC2cXhtlOitrrN 24339741
-
Kantner HP, Warsch W, Delogu A, Bauer E, Esterbauer H, Casanova E, et al. ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells. Neoplasia. 2013;15:1292-300.
-
(2013)
Neoplasia
, vol.15
, pp. 1292-1300
-
-
Kantner, H.P.1
Warsch, W.2
Delogu, A.3
Bauer, E.4
Esterbauer, H.5
Casanova, E.6
-
262
-
-
84874747209
-
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
-
3681503 23458731
-
Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan AS, et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget. 2012;3:1669-87.
-
(2012)
Oncotarget
, vol.3
, pp. 1669-1687
-
-
Warsch, W.1
Grundschober, E.2
Berger, A.3
Gille, L.4
Cerny-Reiterer, S.5
Tigan, A.S.6
-
263
-
-
33644747418
-
HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth
-
1410808 1:CAS:528:DC%2BD28Xit1Kmtb0%3D 16510872
-
Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006;20:557-70.
-
(2006)
Genes Dev
, vol.20
, pp. 557-570
-
-
Covello, K.L.1
Kehler, J.2
Yu, H.3
Gordan, J.D.4
Arsham, A.M.5
Hu, C.J.6
-
264
-
-
34247527730
-
Hypoxia-inducible factors, stem cells, and cancer
-
3150586 1:CAS:528:DC%2BD2sXlvVGktbw%3D 17482542
-
Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129:465-72.
-
(2007)
Cell
, vol.129
, pp. 465-472
-
-
Keith, B.1
Simon, M.C.2
-
265
-
-
84863910743
-
Recent advances in acute myeloid leukemia stem cell biology
-
3396664 1:CAS:528:DC%2BC3sXjs1Sqtg%3D%3D 22511496
-
Horton SJ, Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology. Haematologica. 2012;97:966-74.
-
(2012)
Haematologica
, vol.97
, pp. 966-974
-
-
Horton, S.J.1
Huntly, B.J.2
-
266
-
-
68649098954
-
Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymphoblastic leukemia
-
1:CAS:528:DC%2BD1MXhtVegs7nO 19446879
-
Oh SH, Park TS, Kim HR, Lee JY, Kim JH, Shin JH, et al. Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymphoblastic leukemia. Leuk Res. 2009;33:e195-8.
-
(2009)
Leuk Res
, vol.33
, pp. 195-198
-
-
Oh, S.H.1
Park, T.S.2
Kim, H.R.3
Lee, J.Y.4
Kim, J.H.5
Shin, J.H.6
-
267
-
-
0034990241
-
What can we learn from leukemia as for the process of lineage commitment in hematopoiesis?
-
1:CAS:528:DC%2BD3MXjvFOntL4%3D 11342300
-
Schmidt CA, Przybylski GK. What can we learn from leukemia as for the process of lineage commitment in hematopoiesis? Int Rev Immunol. 2001;20:107-15.
-
(2001)
Int Rev Immunol
, vol.20
, pp. 107-115
-
-
Schmidt, C.A.1
Przybylski, G.K.2
-
268
-
-
58549099651
-
Phenotype of blasts in chronic myeloid leukemia in blastic phase-analysis of bone marrow trephine biopsies and correlation with cytogenetics
-
18760473
-
Reid AG, De Melo VA, Elderfield K, Clark I, Marin D, Apperley J, et al. Phenotype of blasts in chronic myeloid leukemia in blastic phase-analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leuk Res. 2009;33:418-25.
-
(2009)
Leuk Res
, vol.33
, pp. 418-425
-
-
Reid, A.G.1
De Melo, V.A.2
Elderfield, K.3
Clark, I.4
Marin, D.5
Apperley, J.6
-
269
-
-
0021999706
-
Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia
-
1:STN:280:DyaL2M7it1Gmsg%3D%3D 3855651
-
Bettelheim P, Lutz D, Majdic O, Paietta E, Haas O, Linkesch W, et al. Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia. Br J Haematol. 1985;59:395-409.
-
(1985)
Br J Haematol
, vol.59
, pp. 395-409
-
-
Bettelheim, P.1
Lutz, D.2
Majdic, O.3
Paietta, E.4
Haas, O.5
Linkesch, W.6
-
270
-
-
64649099664
-
The 8p11 myeloproliferative syndrome: Review of literature and an illustrative case report
-
2480578 1:CAS:528:DC%2BD1cXpt1Gnurw%3D 18787627
-
Goradia A, Bayerl M, Cornfield D. The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report. Int J Clin Exp Pathol. 2008;1:448-56.
-
(2008)
Int J Clin Exp Pathol
, vol.1
, pp. 448-456
-
-
Goradia, A.1
Bayerl, M.2
Cornfield, D.3
-
271
-
-
49149127176
-
Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3
-
1:STN:280:DC%2BD1cvot12ltQ%3D%3D 18663058
-
Tzankov A, Sotlar K, Muhlematter D, Theocharides A, Went P, Jotterand M, et al. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. J Clin Pathol. 2008;61:958-61.
-
(2008)
J Clin Pathol
, vol.61
, pp. 958-961
-
-
Tzankov, A.1
Sotlar, K.2
Muhlematter, D.3
Theocharides, A.4
Went, P.5
Jotterand, M.6
-
272
-
-
0036210049
-
Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis
-
1:CAS:528:DC%2BD38XitlGmtrs%3D 11919425
-
Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002;127:140-2.
-
(2002)
Int Arch Allergy Immunol
, vol.127
, pp. 140-142
-
-
Sperr, W.R.1
Horny, H.P.2
Valent, P.3
-
273
-
-
3142767799
-
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas
-
1:CAS:528:DC%2BD2cXlslKrurg%3D 15254283
-
Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004;351:250-9.
-
(2004)
N Engl J Med
, vol.351
, pp. 250-259
-
-
Streubel, B.1
Chott, A.2
Huber, D.3
Exner, M.4
Jager, U.5
Wagner, O.6
-
274
-
-
0034643676
-
Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells
-
1:CAS:528:DC%2BD3cXjvFSkurc%3D 10905245
-
Gunsilius E, Duba HC, Petzer AL, Kahler CM, Grunewald K, Stockhammer G, et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet. 2000;355:1688-91.
-
(2000)
Lancet
, vol.355
, pp. 1688-1691
-
-
Gunsilius, E.1
Duba, H.C.2
Petzer, A.L.3
Kahler, C.M.4
Grunewald, K.5
Stockhammer, G.6
-
275
-
-
57549084082
-
Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia
-
18951692
-
Wu J, Huang L, Huang M, Liu W, Zheng M, Cao Y, et al. Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia. Exp Hematol. 2009;37:87-91.
-
(2009)
Exp Hematol
, vol.37
, pp. 87-91
-
-
Wu, J.1
Huang, L.2
Huang, M.3
Liu, W.4
Zheng, M.5
Cao, Y.6
-
276
-
-
67349158886
-
Vasculogenic mimicry of acute leukemic bone marrow stromal cells
-
1:CAS:528:DC%2BD1MXntFygt7c%3D 19340002
-
Mirshahi P, Rafii A, Vincent L, Berthaut A, Varin R, Kalantar G, et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia. 2009;23:1039-48.
-
(2009)
Leukemia
, vol.23
, pp. 1039-1048
-
-
Mirshahi, P.1
Rafii, A.2
Vincent, L.3
Berthaut, A.4
Varin, R.5
Kalantar, G.6
-
277
-
-
33845595255
-
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells
-
1:CAS:528:DC%2BD2sXitlyisrc%3D 17181570
-
Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest. 2007;37:73-82.
-
(2007)
Eur J Clin Invest
, vol.37
, pp. 73-82
-
-
Hauswirth, A.W.1
Florian, S.2
Printz, D.3
Sotlar, K.4
Krauth, M.T.5
Fritsch, G.6
-
278
-
-
32244442420
-
Implications of the expression of myeloid markers on normal and leukemic stem cells
-
1:CAS:528:DC%2BD28XjvFOmtL8%3D 16397415
-
Pearce DJ, Taussig DC, Bonnet D. Implications of the expression of myeloid markers on normal and leukemic stem cells. Cell Cycle. 2006;5:271-3.
-
(2006)
Cell Cycle
, vol.5
, pp. 271-273
-
-
Pearce, D.J.1
Taussig, D.C.2
Bonnet, D.3
-
279
-
-
0036733277
-
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
-
1:CAS:528:DC%2BD38XmsV2lt7o%3D 12200674
-
Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627-36.
-
(2002)
Leukemia
, vol.16
, pp. 1627-1636
-
-
Larson, R.A.1
Boogaerts, M.2
Estey, E.3
Karanes, C.4
Stadtmauer, E.A.5
Sievers, E.L.6
-
280
-
-
0035397980
-
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
-
1:CAS:528:DC%2BD3MXltlShtbw%3D 11432892
-
Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-54.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3244-3254
-
-
Sievers, E.L.1
Larson, R.A.2
Stadtmauer, E.A.3
Estey, E.4
Lowenberg, B.5
Dombret, H.6
-
281
-
-
0037328497
-
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195
-
1:CAS:528:DC%2BD3sXht1GltLs%3D 12592328
-
Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003;17:314-8.
-
(2003)
Leukemia
, vol.17
, pp. 314-318
-
-
Feldman, E.1
Kalaycio, M.2
Weiner, G.3
Frankel, S.4
Schulman, P.5
Schwartzberg, L.6
-
282
-
-
0033151526
-
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase i study of an anti-CD33 calicheamicin immunoconjugate
-
1:CAS:528:DyaK1MXjsVOnsLk%3D 10339474
-
Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-84.
-
(1999)
Blood
, vol.93
, pp. 3678-3684
-
-
Sievers, E.L.1
Appelbaum, F.R.2
Spielberger, R.T.3
Forman, S.J.4
Flowers, D.5
Smith, F.O.6
-
283
-
-
79952282655
-
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
-
1:CAS:528:DC%2BC3cXhsVWmurnK 21076471
-
Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 2011;30:1009-19.
-
(2011)
Oncogene
, vol.30
, pp. 1009-1019
-
-
Majeti, R.1
-
284
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
-
1:CAS:528:DC%2BC3cXhtlKmtrnP 20965785
-
Mahon F-X, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-35.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1029-1035
-
-
Mahon, F.-X.1
Rea, D.2
Guilhot, J.3
Guilhot, F.4
Huguet, F.5
Nicolini, F.6
-
285
-
-
38549147027
-
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
-
1:CAS:528:DC%2BD1cXhsVOnu7g%3D 18226581
-
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16.
-
(2008)
Lancet Oncol
, vol.9
, pp. 105-116
-
-
Pfreundschuh, M.1
Schubert, J.2
Ziepert, M.3
Schmits, R.4
Mohren, M.5
Lengfelder, E.6
-
286
-
-
78651354250
-
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
-
1:CAS:528:DC%2BC3MXisV2murc%3D 21155758
-
Patz M, Isaeva P, Forcob N, Muller B, Frenzel LP, Wendtner CM, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011;152:295-306.
-
(2011)
Br J Haematol
, vol.152
, pp. 295-306
-
-
Patz, M.1
Isaeva, P.2
Forcob, N.3
Muller, B.4
Frenzel, L.P.5
Wendtner, C.M.6
-
287
-
-
43049162575
-
Alemtuzumab in the treatment of chronic lymphocytic lymphoma
-
1:CAS:528:DC%2BD1cXksFygsL0%3D 18402519
-
Boyd K, Dearden CE. Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Rev Anticancer Ther. 2008;8:525-33.
-
(2008)
Expert Rev Anticancer Ther
, vol.8
, pp. 525-533
-
-
Boyd, K.1
Dearden, C.E.2
-
288
-
-
58149183124
-
Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells
-
1:CAS:528:DC%2BD1cXhsVaiu7jP 18949375
-
Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol. 2008;33:1107-13.
-
(2008)
Int J Oncol
, vol.33
, pp. 1107-1113
-
-
Cunningham, M.P.1
Thomas, H.2
Marks, C.3
Green, M.4
Fan, Z.5
Modjtahedi, H.6
-
289
-
-
77957367410
-
Imatinib treatment of metastatic GIST: Don't stop (believing)
-
20864404
-
Heinrich MC. Imatinib treatment of metastatic GIST: don't stop (believing). Lancet Oncol. 2010;11:910-1.
-
(2010)
Lancet Oncol
, vol.11
, pp. 910-911
-
-
Heinrich, M.C.1
-
290
-
-
23944476155
-
Phase i safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
1:CAS:528:DC%2BD2MXpslOrtL0%3D 15955900
-
Burris 3rd HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23:5305-13.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5305-5313
-
-
Burris, H.A.1
Hurwitz, H.I.2
Dees, E.C.3
Dowlati, A.4
Blackwell, K.L.5
O'Neil, B.6
-
291
-
-
84861856844
-
Efficacy and safety of vismodegib in advanced basal-cell carcinoma
-
1:CAS:528:DC%2BC38XovVehsb8%3D 22670903
-
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-9.
-
(2012)
N Engl J Med
, vol.366
, pp. 2171-2179
-
-
Sekulic, A.1
Migden, M.R.2
Oro, A.E.3
Dirix, L.4
Lewis, K.D.5
Hainsworth, J.D.6
-
292
-
-
79960027865
-
BRAF targeted therapy changes the treatment paradigm in melanoma
-
1:CAS:528:DC%2BC3MXotleltrw%3D 21606968
-
Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8:426-33.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, pp. 426-433
-
-
Ribas, A.1
Flaherty, K.T.2
-
293
-
-
84879748062
-
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
-
3772525 1:CAS:528:DC%2BC3sXhtFygu7zN 23782158
-
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32-42.
-
(2013)
N Engl J Med
, vol.369
, pp. 32-42
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
Flinn, I.W.4
Burger, J.A.5
Blum, K.A.6
-
294
-
-
23944453425
-
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study
-
1:CAS:528:DC%2BD2MXpslOrtLw%3D 15998902
-
Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294-304.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5294-5304
-
-
Galanis, E.1
Buckner, J.C.2
Maurer, M.J.3
Kreisberg, J.I.4
Ballman, K.5
Boni, J.6
-
295
-
-
38749111823
-
MTOR as a target for therapy of renal cancer
-
17998894
-
Hudes GR. mTOR as a target for therapy of renal cancer. Clin Adv Hematol Oncol. 2007;5:772-4.
-
(2007)
Clin Adv Hematol Oncol
, vol.5
, pp. 772-774
-
-
Hudes, G.R.1
-
296
-
-
80055000824
-
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
-
3328300 1:CAS:528:DC%2BC3MXhtFers7%2FP 21814200
-
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524-8.
-
(2011)
Nature
, vol.478
, pp. 524-528
-
-
Zuber, J.1
Shi, J.2
Wang, E.3
Rappaport, A.R.4
Herrmann, H.5
Sison, E.A.6
-
297
-
-
3442877507
-
VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells
-
1:CAS:528:DC%2BD2cXmtlKju7o%3D 15254962
-
Fons P, Herault JP, Delesque N, Tuyaret J, Bono F, Herbert JM. VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol. 2004;200:351-9.
-
(2004)
J Cell Physiol
, vol.200
, pp. 351-359
-
-
Fons, P.1
Herault, J.P.2
Delesque, N.3
Tuyaret, J.4
Bono, F.5
Herbert, J.M.6
-
298
-
-
45949101159
-
Expression of multidrug resistance genes in normal and cancer stem cells
-
1:CAS:528:DC%2BD1cXnsFejt7k%3D 18568776
-
Shervington A, Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 2008;26:535-42.
-
(2008)
Cancer Invest
, vol.26
, pp. 535-542
-
-
Shervington, A.1
Lu, C.2
-
299
-
-
0036176510
-
Mechanisms of cancer drug resistance
-
1:CAS:528:DC%2BD38Xitl2mtLo%3D 11818492
-
Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-27.
-
(2002)
Annu Rev Med
, vol.53
, pp. 615-627
-
-
Gottesman, M.M.1
-
300
-
-
77957937825
-
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells
-
1:CAS:528:DC%2BC3cXhsVSktb3K 20634379
-
Engler JR, Frede A, Saunders V, Zannettino A, White DL, Hughes TP. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood. 2010;116:2776-8.
-
(2010)
Blood
, vol.116
, pp. 2776-2778
-
-
Engler, J.R.1
Frede, A.2
Saunders, V.3
Zannettino, A.4
White, D.L.5
Hughes, T.P.6
-
301
-
-
22244433866
-
Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic
-
1:CAS:528:DC%2BD2MXmt1egsrk%3D 16024622
-
Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005;65:6207-19.
-
(2005)
Cancer Res
, vol.65
, pp. 6207-6219
-
-
Patrawala, L.1
Calhoun, T.2
Schneider-Broussard, R.3
Zhou, J.4
Claypool, K.5
Tang, D.G.6
-
302
-
-
70350150304
-
Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma
-
1:CAS:528:DC%2BD1MXhsVyisrjP 19832037
-
Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, et al. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest. 2009;27:901-8.
-
(2009)
Cancer Invest
, vol.27
, pp. 901-908
-
-
Nakai, E.1
Park, K.2
Yawata, T.3
Chihara, T.4
Kumazawa, A.5
Nakabayashi, H.6
-
303
-
-
70449493049
-
ABCB1 is predominantly expressed in human fetal neural stem/progenitor cells at an early development stage
-
1:CAS:528:DC%2BD1MXoslOns7s%3D 19384922
-
Yamamoto A, Shofuda T, Islam MO, Nakamura Y, Yamasaki M, Okano H, et al. ABCB1 is predominantly expressed in human fetal neural stem/progenitor cells at an early development stage. J Neurosci Res. 2009;87:2615-23.
-
(2009)
J Neurosci Res
, vol.87
, pp. 2615-2623
-
-
Yamamoto, A.1
Shofuda, T.2
Islam, M.O.3
Nakamura, Y.4
Yamasaki, M.5
Okano, H.6
-
304
-
-
77957705615
-
UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs
-
1:CAS:528:DC%2BC3cXht1elsL3N 20037778
-
Jin W, Liu Y, Xu SG, Yin WJ, Li JJ, Yang JM, et al. UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs. Breast Cancer Res Treat. 2010;124:39-48.
-
(2010)
Breast Cancer Res Treat
, vol.124
, pp. 39-48
-
-
Jin, W.1
Liu, Y.2
Xu, S.G.3
Yin, W.J.4
Li, J.J.5
Yang, J.M.6
-
305
-
-
34249669336
-
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
-
1:CAS:528:DC%2BD2sXlsFOiu7o%3D 17519960
-
Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia. 2007;21:1267-75.
-
(2007)
Leukemia
, vol.21
, pp. 1267-1275
-
-
Brendel, C.1
Scharenberg, C.2
Dohse, M.3
Robey, R.W.4
Bates, S.E.5
Shukla, S.6
-
306
-
-
0035886024
-
Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells
-
1:CAS:528:DC%2BD3MXnslCru74%3D 11588023
-
Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-7.
-
(2001)
Blood
, vol.98
, pp. 2301-2307
-
-
Guzman, M.L.1
Neering, S.J.2
Upchurch, D.3
Grimes, B.4
Howard, D.S.5
Rizzieri, D.A.6
-
307
-
-
33646351002
-
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
-
1:CAS:528:DC%2BD28XkvVyku74%3D 16633340
-
Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 2006;441:518-22.
-
(2006)
Nature
, vol.441
, pp. 518-522
-
-
Zhang, J.1
Grindley, J.C.2
Yin, T.3
Jayasinghe, S.4
He, X.C.5
Ross, J.T.6
-
308
-
-
33646376411
-
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
-
1:CAS:528:DC%2BD28XkvVykurY%3D 16598206
-
Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441:475-82.
-
(2006)
Nature
, vol.441
, pp. 475-482
-
-
Yilmaz, O.H.1
Valdez, R.2
Theisen, B.K.3
Guo, W.4
Ferguson, D.O.5
Wu, H.6
-
309
-
-
34247136786
-
Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia
-
1:CAS:528:DC%2BD2sXkvFymsrc%3D 17401010
-
Hess CJ, Berkhof J, Denkers F, Ossenkoppele GJ, Schouten JP, Oudejans JJ, et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol. 2007;25:1209-15.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1209-1215
-
-
Hess, C.J.1
Berkhof, J.2
Denkers, F.3
Ossenkoppele, G.J.4
Schouten, J.P.5
Oudejans, J.J.6
-
310
-
-
77951571268
-
Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance
-
2868812 20426848
-
Harper LJ, Costea DE, Gammon L, Fazil B, Biddle A, Mackenzie IC. Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer. 2010;10:166.
-
(2010)
BMC Cancer
, vol.10
, pp. 166
-
-
Harper, L.J.1
Costea, D.E.2
Gammon, L.3
Fazil, B.4
Biddle, A.5
Mackenzie, I.C.6
-
311
-
-
20044372154
-
MGMT gene silencing and benefit from temozolomide in glioblastoma
-
1:CAS:528:DC%2BD2MXit1Wktro%3D 15758010
-
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
-
(2005)
N Engl J Med
, vol.352
, pp. 997-1003
-
-
Hegi, M.E.1
Diserens, A.C.2
Gorlia, T.3
Hamou, M.F.4
De Tribolet, N.5
Weller, M.6
-
312
-
-
67650735457
-
DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment
-
1:CAS:528:DC%2BD1MXnt1SisL4%3D 19522503
-
Skladanowski A, Bozko P, Sabisz M. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment. Chem Rev. 2009;109:2951-73.
-
(2009)
Chem Rev
, vol.109
, pp. 2951-2973
-
-
Skladanowski, A.1
Bozko, P.2
Sabisz, M.3
-
313
-
-
69849104865
-
The leukemic stem cell niche: Current concepts and therapeutic opportunities
-
2723012 1:CAS:528:DC%2BD1MXhtVSgsbbF 19401558
-
Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114:1150-7.
-
(2009)
Blood
, vol.114
, pp. 1150-1157
-
-
Lane, S.W.1
Scadden, D.T.2
Gilliland, D.G.3
-
315
-
-
33745714215
-
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: Results of a randomized phase 3 trial
-
1:CAS:528:DC%2BD28XmsVOmtLg%3D 16556892
-
Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108:88-96.
-
(2006)
Blood
, vol.108
, pp. 88-96
-
-
Brune, M.1
Castaigne, S.2
Catalano, J.3
Gehlsen, K.4
Ho, A.D.5
Hofmann, W.K.6
-
316
-
-
77956611808
-
Targeting leukemic stem cells by breaking their dormancy
-
20599449
-
Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 2010;4:443-50.
-
(2010)
Mol Oncol
, vol.4
, pp. 443-450
-
-
Essers, M.A.1
Trumpp, A.2
-
317
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
3549297 1:CAS:528:DC%2BC3cXhtVCrtrbN 20525992
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
318
-
-
84859158384
-
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
-
3319479 1:CAS:528:DC%2BC38XltValu7o%3D 22236695
-
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207-12.
-
(2012)
Curr Opin Immunol
, vol.24
, pp. 207-212
-
-
Topalian, S.L.1
Drake, C.G.2
Pardoll, D.M.3
-
319
-
-
36349010285
-
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
-
1:CAS:528:DC%2BD2sXhtlGis7bM 18032763
-
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-42.
-
(2007)
N Engl J Med
, vol.357
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
Wang, M.4
Belch, A.5
Stadtmauer, E.A.6
-
320
-
-
33748051406
-
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
-
1:CAS:528:DC%2BD28XotFWqsb8%3D 16912155
-
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66:7843-8.
-
(2006)
Cancer Res
, vol.66
, pp. 7843-7848
-
-
Bao, S.1
Wu, Q.2
Sathornsumetee, S.3
Hao, Y.4
Li, Z.5
Hjelmeland, A.B.6
-
321
-
-
0035883060
-
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
-
1:CAS:528:DC%2BD3MXmtFeitrw%3D 11493466
-
Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98:1166-73.
-
(2001)
Blood
, vol.98
, pp. 1166-1173
-
-
Wulf, G.G.1
Wang, R.Y.2
Kuehnle, I.3
Weidner, D.4
Marini, F.5
Brenner, M.K.6
-
322
-
-
4644306516
-
A distinct "side population" of cells with high drug efflux capacity in human tumor cells
-
521140 1:CAS:528:DC%2BD2cXosVyltr8%3D 15381773
-
Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004;101:14228-33.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 14228-14233
-
-
Hirschmann-Jax, C.1
Foster, A.E.2
Wulf, G.G.3
Nuchtern, J.G.4
Jax, T.W.5
Gobel, U.6
-
323
-
-
84897019340
-
The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells
-
24052572
-
Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol. 2014;95:95-104.
-
(2014)
J Leukoc Biol
, vol.95
, pp. 95-104
-
-
Peter, B.1
Cerny-Reiterer, S.2
Hadzijusufovic, E.3
Schuch, K.4
Stefanzl, G.5
Eisenwort, G.6
-
324
-
-
36749061389
-
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo
-
1:CAS:528:DC%2BD2sXhtlWkt7nK 18025273
-
Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, et al. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther. 2007;6:2868-78.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 2868-2878
-
-
Moser, C.1
Lang, S.A.2
Kainz, S.3
Gaumann, A.4
Fichtner-Feigl, S.5
Koehl, G.E.6
-
325
-
-
79955711142
-
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse
-
3135355 1:CAS:528:DC%2BC3MXkvFCrsr0%3D 21464223
-
Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011;208:653-61.
-
(2011)
J Exp Med
, vol.208
, pp. 653-661
-
-
Clappier, E.1
Gerby, B.2
Sigaux, F.3
Delord, M.4
Touzri, F.5
Hernandez, L.6
-
326
-
-
33749609644
-
Chronic myelogenous leukemia (CML): Resistance to tyrosine kinase inhibitors
-
17018738
-
Hochhaus A. Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors. Ann Oncol. 2006;17 Suppl 10:x274-9.
-
(2006)
Ann Oncol
, vol.17
, pp. 274-279
-
-
Hochhaus, A.1
-
327
-
-
58149398623
-
Translation of the Philadelphia chromosome into therapy for CML
-
1:CAS:528:DC%2BD1cXhsFWms7%2FP 19064740
-
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808-17.
-
(2008)
Blood
, vol.112
, pp. 4808-4817
-
-
Druker, B.J.1
-
328
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
1:CAS:528:DC%2BD3MXlvVKrsbs%3D 11423618
-
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-80.
-
(2001)
Science
, vol.293
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
Hsu, N.4
Paquette, R.5
Rao, P.N.6
-
329
-
-
23344440655
-
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
-
1180625 1:CAS:528:DC%2BD2MXnvVWjurg%3D 16046538
-
Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005;102:11011-6.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 11011-11016
-
-
Carter, T.A.1
Wodicka, L.M.2
Shah, N.P.3
Velasco, A.M.4
Fabian, M.A.5
Treiber, D.K.6
-
330
-
-
45749093747
-
Resistance and relapse with imatinib in CML: Causes and consequences
-
1:CAS:528:DC%2BD1cXovVertbw%3D 18397677
-
Deininger M. Resistance and relapse with imatinib in CML: causes and consequences. J Natl Compr Canc Netw. 2008;6 Suppl 2:S11-21.
-
(2008)
J Natl Compr Canc Netw
, vol.6
, pp. 11-21
-
-
Deininger, M.1
-
331
-
-
65249185560
-
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia
-
19337198
-
Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16:122-31.
-
(2009)
Cancer Control
, vol.16
, pp. 122-131
-
-
Quintas-Cardama, A.1
Kantarjian, H.M.2
Cortes, J.E.3
-
332
-
-
0347378578
-
Mechanisms of drug resistance in AML
-
1:CAS:528:DC%2BD3sXisF2iu70%3D 12481719
-
Andreeff M, Konopleva M. Mechanisms of drug resistance in AML. Cancer Treat Res. 2002;112:237-62.
-
(2002)
Cancer Treat Res
, vol.112
, pp. 237-262
-
-
Andreeff, M.1
Konopleva, M.2
-
333
-
-
25144462634
-
Heat shock proteins and acute leukemias
-
1:CAS:528:DC%2BD2MXmt1Glsbs%3D 16019471
-
Thomas X, Campos L, Le QH, Guyotat D. Heat shock proteins and acute leukemias. Hematology. 2005;10:225-35.
-
(2005)
Hematology
, vol.10
, pp. 225-235
-
-
Thomas, X.1
Campos, L.2
Le, Q.H.3
Guyotat, D.4
-
334
-
-
39649094569
-
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients
-
1:CAS:528:DC%2BD1cXot1Sq 17726160
-
Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385-95.
-
(2007)
Blood
, vol.110
, pp. 4385-4395
-
-
Haase, D.1
Germing, U.2
Schanz, J.3
Pfeilstocker, M.4
Nosslinger, T.5
Hildebrandt, B.6
-
335
-
-
48749098918
-
Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype
-
3640813 1:CAS:528:DC%2BD1cXhtFSgsLbK 18692687
-
Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol. 2008;35:365-77.
-
(2008)
Semin Oncol
, vol.35
, pp. 365-377
-
-
Mrozek, K.1
-
336
-
-
0012906888
-
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
-
1:CAS:528:DC%2BD3sXktVGnt7o%3D 12560227
-
Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:3794-800.
-
(2003)
Blood
, vol.101
, pp. 3794-3800
-
-
Cortes, J.E.1
Talpaz, M.2
Giles, F.3
O'Brien, S.4
Rios, M.B.5
Shan, J.6
-
337
-
-
84881298446
-
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
-
1:CAS:528:DC%2BC3sXhtlWltLbP 23803709
-
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-84.
-
(2013)
Blood
, vol.122
, pp. 872-884
-
-
Baccarani, M.1
Deininger, M.W.2
Rosti, G.3
Hochhaus, A.4
Soverini, S.5
Apperley, J.F.6
-
338
-
-
84870012939
-
Ponatinib in refractory Philadelphia chromosome-positive leukemias
-
3777383 1:CAS:528:DC%2BC38XhslyltrvJ 23190221
-
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075-88.
-
(2012)
N Engl J Med
, vol.367
, pp. 2075-2088
-
-
Cortes, J.E.1
Kantarjian, H.2
Shah, N.P.3
Bixby, D.4
Mauro, M.J.5
Flinn, I.6
-
339
-
-
79957500033
-
A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
-
1:CAS:528:DC%2BC3MXmvVaqsr0%3D 21195552
-
Blay JY. A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev. 2011;37:373-84.
-
(2011)
Cancer Treat Rev
, vol.37
, pp. 373-384
-
-
Blay, J.Y.1
-
340
-
-
84881649283
-
Nilotinib for treatment of gastrointestinal stromal tumors: Out of the equation?
-
1:CAS:528:DC%2BC3sXht1KgsrvE 23834614
-
Kanda T, Ishikawa T, Takahashi T, Nishida T. Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation? Expert Opin Pharmacother. 2013;14:1859-67.
-
(2013)
Expert Opin Pharmacother
, vol.14
, pp. 1859-1867
-
-
Kanda, T.1
Ishikawa, T.2
Takahashi, T.3
Nishida, T.4
-
341
-
-
84901506440
-
Review article: The biology, diagnosis and management of gastrointestinal stromal tumours
-
1:CAS:528:DC%2BC2cXos1Wlur8%3D 24749828
-
Iorio N, Sawaya RA, Friedenberg FK. Review article: the biology, diagnosis and management of gastrointestinal stromal tumours. Aliment Pharmacol Ther. 2014;39(12):1376-86.
-
(2014)
Aliment Pharmacol Ther
, vol.39
, Issue.12
, pp. 1376-1386
-
-
Iorio, N.1
Sawaya, R.A.2
Friedenberg, F.K.3
-
342
-
-
84895023201
-
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma
-
1:CAS:528:DC%2BC2cXhtVOmtr4%3D 23959576
-
Shoji S, Nakano M, Sato H, Tang XY, Osamura YR, Terachi T, et al. The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis. 2014;31:111-34.
-
(2014)
Clin Exp Metastasis
, vol.31
, pp. 111-134
-
-
Shoji, S.1
Nakano, M.2
Sato, H.3
Tang, X.Y.4
Osamura, Y.R.5
Terachi, T.6
-
343
-
-
84882781441
-
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
-
1:CAS:528:DC%2BC3sXhtlCrsrbP 23964934
-
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-31.
-
(2013)
N Engl J Med
, vol.369
, pp. 722-731
-
-
Motzer, R.J.1
Hutson, T.E.2
Cella, D.3
Reeves, J.4
Hawkins, R.5
Guo, J.6
-
344
-
-
0037251878
-
Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
-
1:CAS:528:DC%2BD3sXjsF2gtbw%3D 12662126
-
Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803-43.
-
(2003)
Drugs
, vol.63
, pp. 803-843
-
-
Plosker, G.L.1
Figgitt, D.P.2
-
345
-
-
49349095724
-
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
-
1:CAS:528:DC%2BD1cXpt12qtbw%3D 18687642
-
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359:613-26.
-
(2008)
N Engl J Med
, vol.359
, pp. 613-626
-
-
Cheson, B.D.1
Leonard, J.P.2
-
346
-
-
84866876169
-
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
-
3460687 1:CAS:528:DC%2BC38XhsVyru7jJ 22889761
-
Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, et al. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood. 2012;120:2658-68.
-
(2012)
Blood
, vol.120
, pp. 2658-2668
-
-
Agarwal, A.1
Fleischman, A.G.2
Petersen, C.L.3
Mackenzie, R.4
Luty, S.5
Loriaux, M.6
-
347
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
1:CAS:528:DC%2BC3cXnvVaktbk%3D 20525993
-
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9.
-
(2010)
N Engl J Med
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.W.2
Issaragrisil, S.3
Le Coutre, P.4
Etienne, G.5
Lobo, C.6
-
348
-
-
84859836481
-
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
-
1:CAS:528:DC%2BC38XmtVKgt7s%3D 22371878
-
Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119:3403-12.
-
(2012)
Blood
, vol.119
, pp. 3403-3412
-
-
Khoury, H.J.1
Cortes, J.E.2
Kantarjian, H.M.3
Gambacorti-Passerini, C.4
Baccarani, M.5
Kim, D.W.6
-
349
-
-
77953384542
-
Mobilization of hematopoietic stem cells into the peripheral blood
-
1:CAS:528:DC%2BD1MXhsVyqsLbK 21082960
-
Damon LE. Mobilization of hematopoietic stem cells into the peripheral blood. Expert Rev Hematol. 2009;2:717-33.
-
(2009)
Expert Rev Hematol
, vol.2
, pp. 717-733
-
-
Damon, L.E.1
-
350
-
-
56249128987
-
Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells
-
1:CAS:528:DC%2BD1cXht1artrnE 18847313
-
Uy GL, Rettig MP, Cashen AF. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008;8:1797-804.
-
(2008)
Expert Opin Biol Ther
, vol.8
, pp. 1797-1804
-
-
Uy, G.L.1
Rettig, M.P.2
Cashen, A.F.3
-
351
-
-
84862308888
-
Nilotinib exerts direct effects on vascular endothelial cells and may act as a co-trigger of atherosclerosis in patients with Ph plus CML
-
Hadzijusufovic E, Herndlhofer S, Aichberger KJ, Ghanim V, Suppan V, Cerny-Reiterer S, et al. Nilotinib exerts direct effects on vascular endothelial cells and may act as a co-trigger of atherosclerosis in patients with Ph plus CML. Blood. 2011;118:1183-4.
-
(2011)
Blood
, vol.118
, pp. 1183-1184
-
-
Hadzijusufovic, E.1
Herndlhofer, S.2
Aichberger, K.J.3
Ghanim, V.4
Suppan, V.5
Cerny-Reiterer, S.6
-
352
-
-
78650962299
-
BCR-ABL kinase is dead; Long live the CML stem cell
-
3007147 1:CAS:528:DC%2BC3MXis1ygsQ%3D%3D 21157035
-
Perl A, Carroll M. BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest. 2011;121:22-5.
-
(2011)
J Clin Invest
, vol.121
, pp. 22-25
-
-
Perl, A.1
Carroll, M.2
-
353
-
-
84863124648
-
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
-
3286213 1:CAS:528:DC%2BC38XjtVSrs7Y%3D 22184410
-
Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501-10.
-
(2012)
Blood
, vol.119
, pp. 1501-1510
-
-
Hamilton, A.1
Helgason, G.V.2
Schemionek, M.3
Zhang, B.4
Myssina, S.5
Allan, E.K.6
|